Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer by Chiang, AKS et al.
Title Urate oxidase for the prevention and treatment of tumour lysissyndrome in children with cancer
Author(s) Cheuk, DKL; Chiang, AKS; Chan, GCF; Ha, SY
Citation Cochrane Database of Systematic Reviews, 2017,  n. 3, p. articleno. CD006945:1-71
Issued Date 2017
URL http://hdl.handle.net/10722/241618
Rights
‘This review is published as a Cochrane Review in the Cochrane
Database of Systematic Reviews 2017, Issue 3. Cochrane
Reviews are regularly updated as new evidence emerges and in
response to comments and criticisms, and the Cochrane
Database of Systematic Reviews should be consulted for the
most recent version of the Review.’
Reference to the Review and hyperlink to the original version:
Authors. Title of Review. Cochrane Database of Systematic
Reviews 2017, Issue 3. Art. No.: CD006945.
DOI: 10.1002/14651858.CD006945.pub4
Persistent link to the article by using the URL: :
http://dx.doi.org/10.1002/14651858.CD006945.pub4
(The most recent issue of the Cochrane Database of Systematic
Reviews in which the Review published: The current version is
shown in above persistent link to the article); This work is
licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.
Cochrane Database of Systematic Reviews
Urate oxidase for the prevention and treatment of tumour
lysis syndrome in children with cancer (Review)
Cheuk DKL, Chiang AKS, Chan GCF, Ha SY
Cheuk DKL, Chiang AKS, Chan GCF, Ha SY.
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD006945.
DOI: 10.1002/14651858.CD006945.pub4.
www.cochranelibrary.com
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
19ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
22DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Urate oxidase compared with allopurinol, Outcome 1 Incidence of clinical tumour lysis
syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Analysis 1.2. Comparison 1 Urate oxidase compared with allopurinol, Outcome 2 Incidence of clinical tumour lysis
syndrome in B-ALL subgroup. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 1.3. Comparison 1 Urate oxidase compared with allopurinol, Outcome 3 All-cause mortality. . . . . . 49
Analysis 1.4. Comparison 1 Urate oxidase compared with allopurinol, Outcome 4 Mortality due to tumour lysis
syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Analysis 1.5. Comparison 1 Urate oxidase compared with allopurinol, Outcome 5 Renal failure requiring renal replacement
therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Analysis 1.6. Comparison 1 Urate oxidase compared with allopurinol, Outcome 6 Renal failure requiring renal replacement
therapy in B-ALL subgroup. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Analysis 1.7. Comparison 1 Urate oxidase compared with allopurinol, Outcome 7 AUC of serum uric acid level at 4 days. 52
Analysis 1.8. Comparison 1 Urate oxidase compared with allopurinol, Outcome 8 AUC of serum uric acid level at 4 days
in leukaemia participants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 1.9. Comparison 1 Urate oxidase compared with allopurinol, Outcome 9 AUC of serum uric acid level at 4 days
in lymphoma participants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Analysis 1.10. Comparison 1 Urate oxidase compared with allopurinol, Outcome 10 AUC of serum uric acid level at 4 days
in hyperuricemic participants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Analysis 1.11. Comparison 1 Urate oxidase compared with allopurinol, Outcome 11 AUC of serum uric acid level at 4 days
in normouricemic participants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Analysis 1.12. Comparison 1 Urate oxidase compared with allopurinol, Outcome 12 Serum uric acid level at 2 days. 56
Analysis 1.13. Comparison 1 Urate oxidase compared with allopurinol, Outcome 13 Serum uric acid level at 3 days. 57
Analysis 1.14. Comparison 1 Urate oxidase compared with allopurinol, Outcome 14 Serum uric acid level at 4 days. 58
Analysis 1.15. Comparison 1 Urate oxidase compared with allopurinol, Outcome 15 Serum uric acid level at 7 days. 59
Analysis 1.16. Comparison 1 Urate oxidase compared with allopurinol, Outcome 16 Serum uric acid level at 1 day. . 59
Analysis 1.17. Comparison 1 Urate oxidase compared with allopurinol, Outcome 17 Serum uric acid level at 5 days. 60
Analysis 1.18. Comparison 1 Urate oxidase compared with allopurinol, Outcome 18 Serum uric acid level at 12 days. 61
Analysis 1.19. Comparison 1 Urate oxidase compared with allopurinol, Outcome 19 Frequency of adverse events. . 61
Analysis 2.1. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 1 Normalisation of
serum uric acid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
iUrate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 2 Percentage
reduction in serum uric acid level at 4 hours. . . . . . . . . . . . . . . . . . . . . . . . 63
Analysis 2.3. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 3 Frequency of
adverse events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
64APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
66WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
67HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
67CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
67DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
68SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
68DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
68INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiUrate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Urate oxidase for the prevention and treatment of tumour
lysis syndrome in children with cancer
Daniel KL Cheuk1, Alan KS Chiang1 , Godfrey CF Chan1, Shau Yin Ha1
1Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Contact address: Daniel KL Cheuk, Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary
Hospital, Pokfulam Road, Hong Kong, China. cheukkld@hkucc.hku.hk.
Editorial group: Cochrane Childhood Cancer Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 3, 2017.
Citation: Cheuk DKL, Chiang AKS, Chan GCF, Ha SY. Urate oxidase for the prevention and treatment of tumour ly-
sis syndrome in children with cancer. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD006945. DOI:
10.1002/14651858.CD006945.pub4.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Tumour lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Previous reviews did
not find clear evidence of benefit of urate oxidase in children with cancer. This review is the second update of a previously published
Cochrane review.
Objectives
To assess the effects and safety of urate oxidase for the prevention and treatment of TLS in children with malignancies.
Search methods
InMarch 2016 we searchedCENTRAL,MEDLINE, Embase, andCINAHL. In addition, we searched the reference lists of all identified
relevant papers, trials registers and other databases. We also screened conference proceedings and we contacted experts in the field and
the manufacturer of rasburicase, Sanofi-aventis.
Selection criteria
Randomised controlled trials (RCT) and controlled clinical trials (CCT) of urate oxidase for the prevention or treatment of TLS in
children under 18 years with any malignancy.
Data collection and analysis
Two review authors independently extracted trial data and assessed individual trial quality. We used risk ratios (RR) for dichotomous
data and mean difference (MD) for continuous data.
Main results
We included seven trials, involving 471 participants in the treatment groups and 603 participants in the control groups. No new studies
were identified in the update. One RCT and five CCTs compared urate oxidase and allopurinol. Three trials tested Uricozyme, and
three trials tested rasburicase for the prevention of TLS.
The RCT did not evaluate the primary outcome (incidence of clinical TLS). It showed no clear evidence of a difference in mortality
(both all-cause mortality (Fisher’s exact test P = 0.23) and mortality due to TLS (no deaths in either group)), renal failure (Fisher’s
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exact test P = 0.46), and adverse effects between the treatment and the control groups (Fisher’s exact test P = 1.0). The frequency of
normalisation of uric acid at four hours (10 out of 10 participants in the treatment group versus zero out of nine participants in the
control group, Fisher’s exact test P < 0.001) and area under the curve of uric acid at four days (MD -201.00 mg/dLhr, 95% CI -258.05
mg/dLhr to -143.95 mg/dLhr; P < 0.00001) were significantly better in the treatment group.
One CCT evaluated the primary outcome; no clear evidence of a difference was identified between the treatment and the control
groups (RR 0.77, 95% CI 0.44 to 1.33; P = 0.34). Pooled results of three CCTs showed significantly lower mortality due to TLS in
the treatment group (RR 0.05, 95% CI 0.00 to 0.89; P = 0.04); no clear evidence of a difference in all-cause mortality was identified
between the groups (RR 0.19, 95% CI 0.01 to 3.42; P = 0.26). Pooled results from five CCTs showed significantly lower incidence of
renal failure in the treatment group (RR 0.26, 95% CI 0.08 to 0.89; P = 0.03). Results of CCTs also showed significantly lower uric
acid in the treatment group at two days (three CCTs: MD -3.80 mg/dL, 95% CI -7.37 mg/dL to -0.24 mg/dL; P = 0.04), three days
(two CCTs: MD -3.13 mg/dL, 95% CI -6.12 mg/dL to -0.14 mg/dL; P = 0.04), four days (two CCTs: MD -4.60 mg/dL, 95% CI -
6.39 mg/dL to -2.81 mg/dL; P < 0.00001), and seven days (one CCT: MD -1.74 mg/dL, 95% CI -3.01 mg/dL to -0.47 mg/dL; P =
0.007) after therapy, but not one day (three CCTs: MD -3.00 mg/dL, 95% CI -7.61 mg/dL to 1.60 mg/dL; P = 0.2), five days (one
CCT: MD -1.02 mg/dL, 95% CI -2.24 mg/dL to 0.20 mg/dL; P = 0.1), and 12 days (one CCT: MD -0.80 mg/dL, 95% CI -2.51 mg/
dL to 0.91 mg/dL; P = 0.36) after therapy. Pooled results from three CCTs showed higher frequency of adverse effects in participants
who received urate oxidase (RR 9.10, 95% CI 1.29 to 64.00; P = 0.03).
Another included RCT, with 30 participants, compared different doses of rasburicase (0.2 mg/kg versus 0.15 mg/kg). The primary
outcome was not evaluated. No clear evidence of a difference in mortality (all-cause mortality (Fisher’s exact test P = 1.0) and mortality
due to TLS (no deaths in both groups)) and renal failure (no renal failure in both groups) was identified. It demonstrated no clear
evidence of a difference in uric acid normalisation (RR 1.07, 95% CI 0.89 to 1.28; P = 0.49) and uric acid level at four hours (MD
8.10%, 95% CI -0.99% to 17.19%; P = 0.08). Common adverse events of urate oxidase included hypersensitivity, haemolysis, and
anaemia, but no clear evidence of a difference between treatment groups was identified (RR 0.54, 95% CI 0.12 to 2.48; P = 0.42).
The quality of evidence ranks from very low to low because of imprecise results, and all included trials were highly susceptible to biases.
Authors’ conclusions
Although urate oxidase might be effective in reducing serum uric acid, it is unclear whether it reduces clinical TLS, renal failure, or
mortality. Adverse effects might be more common for urate oxidase compared with allopurinol. Clinicians should weigh the potential
benefits of reducing uric acid and uncertain benefits of preventing mortality or renal failure from TLS against the potential risk of
adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Urate oxidase for the prevention and treatment of complications from massive lysis (breakdown) of tumour cells in children
with cancer
Review question
We reviewed the evidence of the effects and safety of urate oxidase for the prevention and treatment of tumour lysis syndrome (TLS)
in children with malignancies.
Background
TLS occurs when uric acid and other cellular substances are rapidly released into the circulation when tumour cells are broken down
spontaneously or during treatment. Uric acid does not dissolve easily, therefore it can build up in the kidney, resulting in kidney failure
and possibly death. Urate oxidase is an enzyme that can be administered to people at risk of TLS to convert uric acid to allantoin, which
is easily dissolved and then readily excreted by the kidneys. Therefore, urate oxidase may be able to prevent or treat TLS in people with
malignancies.
Study characteristics
The evidence is current to March 2016.
We found seven trials (1074 participants). No new studies were identified in this update. Six studies compared urate oxidase and
allopurinol. Three trials tested Uricozyme, and three trials tested rasburicase. One study (30 participants) compared different doses of
rasburicase.
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Key results
The current systematic review of (randomised) controlled clinical trials found that although urate oxidase might be effective in reducing
serum uric acid level, it has not been confirmed to reduce renal failure or mortality from TLS in children with cancer. Adverse effects
might be more common in people who receive urate oxidase compared with allopurinol. Urate oxidase needs to be further evaluated,
especially in high-risk patients, such as those with high-risk leukaemia and lymphoma.
Quality of the evidence
The quality of evidence ranks from very low to low because of imprecise results, and all included trials were highly susceptible to biases.
3Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Urate oxidase compared with allopurinol for prevention of tumour lysis syndrome
Patient or population: children with haematological malignancy at risk of tumour lysis syndrome
Settings: hospital inpatient
Intervention: urate oxidase
Comparison: allopurinol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Allopurinol Urate oxidase
Incidence of clinical tu-
mour lysis syndrome
(follow-up: unknown)
161 per 1000 124 per 1000
(71 to 214)
RR 0.77 (0.44 to 1.33) 348
(1)
⊕⊕©©
lowa
Mortality due to tumour
lysis syndrome
(follow-up: 4 to 12 days)
51 per 1000b 3 per 1000
(0 to 45)
RR 0.05 (0 to 0.89) 396
(3)
⊕⊕©©
lowa
Renal failure requir-
ing renal replacement
therapy
(follow-up: 4 to 13 days)
92 per 1000 24 per 1000
(7 to 82)
RR 0.26 (0.08 to 0.89) 992
(5)
⊕©©©
very lowc
Normalisation of
serum uric acid
0 per 1000 1000 per 1000d
(conf idence interval not
est imable)
Not applicable 19
(1)
⊕⊕©©
lowa
None of 9 part icipants
in the control group and
all 10 part icipants in the
intervent ion group had
normalisat ion of serum
uric acid
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Percentage reduction
in serum uric acid level
Not reported Not reported Not applicable Not applicable Not applicable None of the studies re-
ported on this outcome
measure
AUC of serum uric acid
level at 4 days
(follow-up: 2 weeks)
The mean AUCof serum
uric acid level in the
control group was 329
mg/dLhr
Themean AUCof serum
uric acid level in the in-
tervent ion groups was
201 mg/dLhr lower
(144 mg/ dLhr to 258
mg/ dLhr lower)
52
(1)
⊕⊕©©
lowa
Frequency of adverse
events
(follow-up: 4 to 13 days)
0 per 1000 52 per 1000e
(0 to 167)
RR 9.10 (1.29 to 64) 345
(3)
⊕⊕©©
lowa
None of part icipants in
the control groups had
adverse events
* The basis for the assumed risk is the median control group risk across studies unless otherwise specif ied. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AUC: area under the curve; CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aEvidence f rom RCT downgraded by two levels because of high risk of bias in study design and imprecise result .
bSince two of three studies had zero control group risks, we used mean instead of median control group risk across studies
as the assumed risk.
cEvidence f rom RCT downgraded by three levels because of high risk of bias in study design, imprecise result and high
heterogeneity.
dSince control group risk (assumed risk) was zero, corresponding risk est imation was based on risk in the intervent ion group
in the included study.
eSince control group risk (assumed risk) was zero, corresponding risk est imation was based on the median and the range of
risks in the intervent ion groups in included studies.
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B A C K G R O U N D
Tumour lysis syndrome (TLS) is a serious complication of malig-
nancies that can occur spontaneously in the presence of rapidly
proliferating tumour cells or during treatment because of rapid cell
lysis, leading to release of intracellular components that may result
in hyperkalaemia, hyperphosphataemia, hypocalcaemia, or hype-
ruricaemia. Hyperuricaemia and hyperphosphataemia can result
in crystallisation in the renal tubules causing obstructive uropathy
and renal failure. Other severe consequences of TLS include car-
diac arrhythmia and sudden death fromhyperkalaemia (Navolanic
2003; Rampello 2006). The Cairo-Bishop definition for labora-
tory TLS is the development of any two or more of the following
four criteria within three days before or seven days after the initi-
ation of chemotherapy: uric acid level of 8 mg/dL or more; potas-
sium level of 6mmol/L or more; phosphate level of 6.65 mg/dL or
more; and calcium level of 7 mg/dL or less. A 25% increase from
baseline for uric acid, potassium, or phosphate levels or a 25%
decrease from baseline for calcium level is an alternative threshold
(Cairo 2004). The Cairo-Bishop definition for clinical TLS is the
presence of laboratory TLS and one or more of the following three
criteria: serum creatinine level 1.5 times or more than the upper
limit of normal; cardiac arrhythmias; sudden death; or seizures.
Risk factors for TLS include high proliferation rate, large tumour
burden, andhigh chemosensitivity. A highwhite blood cell (WBC)
count in leukaemia (>50 x 10 /L) or a high lactate dehydrogenase
(LDH) level in lymphoma indicates high tumour burden. Certain
malignancies, such as Burkitt’s lymphoma, are associated with a
very high risk of TLS because of rapid tumour cell turnover (
Wössmann 2003). The incidence of TLS varies among studies.
A retrospective review of acute lymphoblastic leukaemia, acute
myeloid leukaemia, and non-Hodgkin’s lymphoma found that the
frequency of TLS was 3.4%, 5.2%, and 6.1%, respectively, and
it accounts for 0.9% of cancer mortality (Annemans 2003a). The
mortality rate of TLS has been estimated to be about 17.5% (
Annemans 2003a). The medical costs of hyperuricaemia and TLS
are substantial. The cost of hyperuricaemia without TLS has been
estimated to be EUR 672 per patient for the whole treatment, and
the cost of TLS, EUR 7342 (Annemans 2003a). The cost of TLS
requiring dialysis has been shown to be even higher (EUR 17,706
on average) (Annemans 2003a).
Aggressive hydration and allopurinol, with or without urinary al-
kalinization with bicarbonate, is the standard prophylaxis for TLS.
Allopurinol is a xanthine oxidase inhibitor, which prevents the
formation of uric acid but does not catabolise (so degrade and
detoxify) existing uric acid. Allopurinol is therefore not an effec-
tive treatment for established TLS, since it does not promote uric
acid clearance. Because of the inhibition of xanthine oxidase, al-
lopurinol increases the level of uric acid precursors, hypoxanthine
and xanthine. As xanthine is less soluble than uric acid, it may
precipitate in renal tubules causing xanthine nephropathy (kidney
disease) or xanthine stones (Greene 1969).
Urate oxidase is an alternative agent used for the treatment or pro-
phylaxis of hyperuricaemia in people who are at high risk of TLS.
Urate oxidase converts uric acid to allantoin, which is five to 10
times more soluble than uric acid and readily excreted in urine. A
non-recombinant form of urate oxidase has been available in Eu-
rope for more than 20 years, but it is associated with acute hyper-
sensitivity reactions in 4.5% of patients (Yim 2003). Rasburicase,
a relatively new, recombinant urate oxidase enzyme produced by
a genetically modified Saccharomyces cerevisiae strain, has now re-
placed the older agent and is widely used. Reported advantages of
urate oxidase over allopurinol include its ability to catabolise exist-
inguric acid in establishedTLS; no increased risk of xanthine stone
formation; no requirement for dose adjustment in acute renal fail-
ure; lack of clinically relevant drug-drug interaction; and lower in-
cidence of adverse reactions, such as skin rash, fever, eosinophilia,
and Stevens Johnson syndrome (Gutierrez-Macias 2005; Sanofi
2011). Anecdotal reports and case series have indicated that urate
oxidase may be effective in the prevention and treatment of TLS
(Bosly 2003; Coiffier 2003; Hummel 2003; Hutcherson 2006;
Jeha 2005; Lascombes 1998; Lee 2003; Liu 2005; McDonnell
2006; Pui 2001a; Pui 2001b; Shin 2006; Trifilio 2006; Wang
2006), resulting in a significant reduction of serum uric acid level
and a low incidence of renal failure requiring dialysis. In addition,
the use of urate oxidase has been reported to be cost-effective for
the prevention and treatment of TLS in both children and adults
(Annemans 2003b). However, it is not entirely certain whether the
existing evidence is sufficiently rigorous to support the routine use
of urate oxidase as prophylaxis in children with malignancies at
risk of TLS, or as a treatment for established laboratory or clinical
TLS. It is also uncertain whether single or multiple doses of urate
oxidase should be used or which types of high-risk patients benefit
most from prophylactic administration of urate oxidase. Although
there are consensus guidelines developed for the management of
TLS (Cairo 2010; Coiffier 2008; Tosi 2008), they did not include
the latest evidence from systematic review. Therefore, we exam-
ined the efficacy and safety of urate oxidase in children withmalig-
nancies in a systematic review of RCTs and CCTs (Cheuk 2010;
Cheuk 2014). This is the second update of that systematic review.
O B J E C T I V E S
To assess the effects and safety of urate oxidase for the prevention
and treatment of TLS in children with malignancies.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in the review.
We also planned to include controlled clinical trials (CCTs) if no
(or few) RCTs were available. A CCT is a study that compares one
or more intervention groups to one or more control groups. We
included historical controlled studies.
Types of participants
We included participants under 18 years of age with all types of
cancer, including haematological malignancies and solid tumours.
Types of interventions
We included trials evaluating all preparations of urate oxidase. The
control interventions could be placebo; no treatment; or other
treatment, such as allopurinol. We also included trials comparing
urate oxidase combinedwith other treatment versus the same other
treatment alone, and trials comparing different doses or different
preparations of urate oxidase.
Types of outcome measures
Prevention
For evaluation of urate oxidase as prevention for TLS, we assessed
the following outcome measures.
Primary outcome
1. Incidence of clinical TLS according to Cairo-Bishop
definition (Cairo 2004)
Secondary outcomes
1. Incidence of laboratory TLS according to Cairo-Bishop
definition (Cairo 2004)
2. Mortality associated with TLS and combined with other
reasons
3. Incidence of renal failure requiring renal replacement
therapy associated with TLS
4. Frequency of normalisation of serum uric acid level
5. Duration before normalisation of serum uric acid level
6. Change in serum uric acid level
7. Area under the curve (AUC) of uric acid level
8. Frequency of adverse effects
Treatment
For the evaluation of urate oxidase as treatment for TLS, we as-
sessed the following outcome measures.
Primary outcome
1. Mortality associated with TLS and combined with other
reasons
Secondary outcomes
1. Incidence of renal failure requiring renal replacement
therapy associated with TLS
2. Frequency of normalisation of serum uric acid level
3. Duration before normalisation of serum uric acid level
4. Change in serum uric acid level
5. AUC of uric acid level
6. Change in serum phosphate level
7. Change in serum potassium level
8. Change in serum creatinine level
9. Change in serum calcium level
10. Frequency of adverse effects
Search methods for identification of studies
There was no language restriction in the search and inclusion of
studies.
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in the Cochrane Library (issue 2, 2016), MED-
LINE/PubMed (1966 to 14 March 2016), Embase (Ovid) (1980
to 14 March 2016), and CINAHL (Cumulative Index to Nurs-
ing and Allied Health Literature) (EBSCO) (1982 to 14 March
2016).
The search strategies used for the different electronic databases (us-
ing a combination of controlled vocabulary and text word terms)
are shown in the Appendices (Appendix 1; Appendix 2; Appendix
3; Appendix 4).
We also explored other internet sources (on 15March 2016), using
keywords in Appendix 5:
1. the NHS’ National Research Register (
www.ukctg.nihr.ac.uk/);
2. the US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov/);
3. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch/)
4. metaRegister of Controlled Trials (www.isrctn.com/page/
mrct); and
5. ProQuest Dissertations & Theses Database (
www.proquest.com/).
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Searching other resources
We searched the reference lists of all identified relevant papers for
further studies. We also handsearched abstracts from the meetings
of the ASCO (American Society of Clinical Oncology), ESMO
(European Society for Medical Oncology), and SIOP (Interna-
tional Society of Paediatric Oncology) from 1993 up to and in-
cluding 2015, using keywords in Appendix 6.
We also included articles published only in abstract form if we
could contact the authors to provide essential details for appraisal
and analysis. If the process of searching many different sources
brought to light direct or indirect references to unpublished stud-
ies, we planned to obtain copies of such unpublished material.
In addition, we contacted colleagues and experts in the field to
ascertain any unpublished or ongoing studies. We also contacted
the manufacturer of rasburicase, Sanofi-aventis, for published and
unpublished clinical studies.
Data collection and analysis
Selection of studies
Two authors (the first and second authors) independently reviewed
titles and abstracts of references retrieved from the searches and
selected all potentially relevant studies. The same authors obtained
copies of these articles and reviewed them independently against
the above-mentioned inclusion and exclusion criteria for study se-
lection. Authors were not blinded to the names of the trial authors,
institutions, or journal of publication. We planned for the third
author to resolve any discrepancies regarding selection of studies
if necessary, but there was no discrepancy and the third author
was not called upon. We have constructed a flow diagram. We
excluded multiple publications reporting the same group of par-
ticipants or its subsets.
Data extraction and management
Two authors extracted data from included trials, independently.
We planned for the third author to resolve any discrepancies re-
garding data extraction if necessary, but there was no discrepancy
and the third author was not called upon.
We extracted the following data.
1. Study methods
i) design (i.e. RCT or CCT)
ii) randomisation method (including list generation)
iii) method of allocation concealment
iv) blinding method
v) stratification factors
2. Participants
i) inclusion/exclusion criteria
ii) number of participants entering the trial, number of
participants randomised, number of excluded participants (with
reasons), and number of evaluable participants
iii) age and gender distribution
iv) type of malignancies
v) treatments for the malignancies (chemotherapy,
radiotherapy, autologous stem cell transplant, allogeneic stem
cell transplant)
vi) baseline renal function, uric acid level, potassium level,
phosphate level, calcium level, lactate dehydrogenase (LDH)
level, white blood cell (WBC) counts (for leukaemia), rate of
decrease of WBC (for leukaemia), and sizes of the liver and spleen
3. Intervention and control
i) type of uric oxidase
ii) type of control treatment
iii) details of administration of urate oxidase, including
dosage and schedules
iv) details of co-interventions
4. Follow-up data
i) duration of follow-up
ii) loss to follow up
5. Outcome data
i) serial uric acid levels measurement
ii) days to normalisation of uric acid level
iii) number of criteria of laboratory TLS according to
Cairo-Bishop definition (Cairo 2004)
iv) number of criteria of clinical TLS according to Cairo-
Bishop definition (Cairo 2004)
v) change in serum potassium, calcium, phosphorus, and
creatinine levels
vi) adverse effects
6. Analysis data
i) methods of analysis (intention-to-treat or per-protocol
analysis)
ii) comparability of groups at baseline (yes/no);
iii) statistical methods
One author entered the data into Review Manager 5 (RevMan 5)
(RevMan 2014); the other authors then checked the data.
Assessment of risk of bias in included studies
Two authors (the first and second authors) independently assessed
the methodological quality of each eligible trial. We planned for
the third author to resolve any discrepancies regarding risk of bias
assessment if necessary, but there was no discrepancy and the third
author was not called upon.Where necessary, we sought additional
information from the principal investigator of the trial concerned.
We included the following items to assess themethodological qual-
ity of RCTs in the update of the review, according to the latest
recommendation in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) and the most recent ’Risk of bias’
criteria as recommended byCochrane Childhood Cancer (Kremer
2016):
1. random sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
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4. blinding of outcome assessment (detection bias) - each
outcome was assessed separately;
5. incomplete outcome data (attrition bias) - each outcome
was assessed separately;
6. selective reporting (reporting bias); and
7. other bias.
Similarly, we assessed controlled clinical trials for the above-men-
tioned types of biases; we expected them not to incorporate ran-
dom allocation of treatment groups or perform allocation conceal-
ment. Because of non-random treatment group allocation, they
were also susceptible to confounding, and we examined possible
confounding factors, including age of the participant, types of ma-
lignancies, baseline renal function, WBC counts, LDH level, uric
acid levels, and intensity of chemotherapy.
Measures of treatment effect
We used risk ratio (RR) estimations with 95% confidence inter-
vals (CI) for dichotomous outcomes. We did not calculate a RR if
there was only one study available for a particular outcome, and
there was no event in one of the groups. We used the Fisher’s exact
test (performed using SPSS version 19 (SPSS 2010)) to determine
the P value in such situations. We used mean difference (MD) es-
timations with 95% CI for continuous outcomes. We analysed all
participants in the treatment groups to which they were allocated
(intention-to-treat (ITT) analyses) if there were no missing data;
we planned to performper-protocol analyses if information for in-
tention-to-treat analyses was lacking. We did not impute missing
data. We planned to consider cost-effectiveness of interventions if
relevant data were available.
Dealing with missing data
We contacted the authors of included studies to ask them to supply
missing data. We assessed missing data and dropouts/attrition for
each included study and assessed and discussed the extent to which
the missing data could alter the results/conclusions of the review.
If, for a particular outcome, less than 70% of participants allocated
to the treatments were reported on at the end of the trial, we
reported those data, but considered them prone to bias.
Assessment of reporting biases
We planned to generate a funnel plot (effect size against standard
error) if we found sufficient studies (more than five). Asymmetry
could be due to publication bias, but could also be due to a re-
lationship between trial size and effect size. In the event that we
found a relationship, we planned to examine clinical diversity of
the studies (Egger 1997). However, there were not enough studies
available to prepare a reliable funnel plot.
Data synthesis
Where the interventions were the same or similar enough, we syn-
thesised results in a meta-analysis if there was no important clin-
ical heterogeneity. If no significant statistical heterogeneity was
present, we synthesised the data using a fixed-effect model. If
there was unexplained heterogeneity, we used a random-effects
model in the meta-analysis. We produced a ’Summary of find-
ings’ table for each comparison according to the recommenda-
tions in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Schünemann 2011a), to summarise the results for the
outcomes (incidence of clinical TLS, mortality due to TLS, re-
nal failure requiring renal replacement therapy, normalisation of
serum uric acid, percentage reduction in serum uric acid level,
AUC of serum uric acid level, and frequency of adverse events).
We provided grading of the quality of evidence according to the
GRADE system (Schünemann 2011b) using the GRADE profiler
software (GRADEpro 2015). The GRADE system includes five
criteria (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of evidence
(Schünemann 2011b).
Subgroup analysis and investigation of heterogeneity
If data permitted, we conducted subgroup analyses for the follow-
ing:
1. different types of malignancies (acute leukaemia,
lymphoma, solid tumour);
2. different number of doses of urate oxidase (single dose, two
doses, three or more doses); and
3. different levels of risk of TLS (participants with rapid cell
turnover, high LDH, or baseline hyperuricaemia).
If two or more included trials reported the same outcomes for
the same subgroups, and no significant heterogeneity was present,
we combined their results in meta-analyses. We assessed clinical
heterogeneity by comparing the distribution of important partic-
ipant factors between trials (age, type of malignancies) and trial
factors (randomisation concealment, blinding of outcome assess-
ment, losses to follow-up, treatment regimens). We assessed statis-
tical heterogeneity of RCTs by examining the I² statistic (Higgins
2002), a quantity that describes approximately the proportion of
variation in point estimates that is due to heterogeneity rather than
sampling error. If significant heterogeneity was present (i.e. I² ≥
50% (Deeks 2011), we explored the trials to investigate possible
explanations.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the impact of
study quality, including the following:
1. all studies; and
2. only those studies with adequate allocation concealment.
We also planned to conduct sensitivity analyses to assess the impact
of heterogeneity, by excluding those with outlying results.
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R E S U L T S
Description of studies
Results of the search
On August 25th 2009, we retrieved 17 articles from the
Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library. We excluded 16 based on title or abstract,
and we included one (Goldman 2001). The electronic search re-
trieved 68 articles from MEDLINE. We excluded 64 based on
title or abstract, because of obvious irrelevance. We examined the
full texts of the four remaining articles. Two were RCTs satis-
fying the inclusion criteria (Goldman 2001; Kikuchi 2009), of
which Goldman 2001 had already been identified in the CEN-
TRAL search. The other two were controlled clinical trials (CCTs)
(Renyi 2007; Wossmann 2003). We included these two CCTs in
the review because we only identified two RCTs. We also retrieved
100 articles from Embase. We excluded all but two articles af-
ter examining the title and abstract. The MEDLINE search also
identified these two articles (Kikuchi 2009; Renyi 2007). We re-
trieved 40 articles from CINAHL, excluding 37 based on title or
abstract. The remaining three articles were the same as those iden-
tified and included from CENTRAL and MEDLINE (Goldman
2001; Renyi 2007; Wossmann 2003).We identified and included
one more CCT (Patte 2002) after checking the reference lists of
the other included studies. We identified no additional completed
or ongoing trials after checking internet sources and conference
proceedings and contacting experts. There was no discrepancy in
the independent selection of included studies among the two au-
thors, and a third author was not necessary in this process.
With the updated electronic search strategy on 26 February 2013,
we retrieved 16 articles from CENTRAL, 53 articles from MED-
LINE, 18 articles from Embase, and no articles from CINAHL.
We found five studies from checking references of included stud-
ies and two studies from the US National Institutes of Health
Ongoing Trials Register. We identified no studies by scanning the
conference proceedings and contacting experts. In summary, we
found a total of 94 studies in the update search in February 2013.
After we removed duplicates, we screened 81 articles for eligibility.
We excluded 69 articles based on title or abstract. We obtained the
full text of the remaining 12 articles. We included seven studies
in this review, including the five studies included in the original
search (Goldman 2001; Kikuchi 2009; Patte 2002; Rényi 2007;
Wössmann 2003) and two additional studies in the update (Pui
1997; Sánchez Tatay 2010). Two studies were ongoing (see the
Characteristics of ongoing studies tables) and did not have results
available, and we excluded three studies (see the Characteristics
of excluded studies tables). There was no discrepancy in the inde-
pendent selection of included studies among the two authors, and
a third author was not necessary in this process.
With the updated electronic search on 14 March 2016, we
retrieved additional 24 records from CENTRAL, 15 records
from MEDLINE, 11 records from Embase and six records from
CINAHL. We found no additional relevant studies in searching
the clinical trials databases and scanning the conference proceed-
ings and contacting experts. In summary, we found an additional
56 records in the update search in March 2016. After we removed
duplicates, we screened 43 records for eligibility and none of these
records were included based on the title or abstract. Since there
was no new relevant study, we did not check references in this
update.
In summary (see Figure 1), we included seven studies (five identi-
fied in the original review and two in the update 2013 and none
in the update 2016). Among the seven included studies, two were
RCTs satisfying the inclusion criteria (Goldman 2001; Kikuchi
2009), and the other five were CCTs (Patte 2002; Pui 1997; Rényi
2007; Sánchez Tatay 2010; Wössmann 2003).
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Figure 1. Study flow diagram of review update
Included studies
All seven included trials evaluated urate oxidase as a preventive
measure for TLS. We identified no clinical trial investigating urate
oxidase for treatment of TLS. We have given details of the in-
cluded trials in the ’Characteristics of included studies’ tables and
summarise the details below.
Six included trials compared urate oxidase against allopurinol
as the control treatment in parallel-group designs (Goldman
2001; Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003). The remaining one included trial compared
different doses of urate oxidase (Kikuchi 2009). Four trials used
rasburicase (Goldman 2001; Kikuchi 2009; Rényi 2007; Sánchez
Tatay 2010)while the remaining three trials usedUricozyme (Patte
2002; Pui 1997;Wössmann 2003). Four included trials (Goldman
2001; Patte 2002; Pui 1997; Rényi 2007) used a standard alkaline
hyperhydration regimen in both the intervention and the con-
trol groups, while one trial (Wössmann 2003) used alkaliniza-
tion only in the control group. The remaining two trials (Kikuchi
2009; Sánchez Tatay 2010) did not mention alkalinization. Six
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trials (Goldman 2001; Kikuchi 2009; Patte 2002; Pui 1997; Rényi
2007; Wössmann 2003) initiated urate oxidase before the start of
chemotherapy, lasting for three to seven days. One trial (Sánchez
Tatay 2010) did not mention the duration of therapy.
None of the five included non-randomised, CCTs used a concur-
rent control group. Four trials used a historical control group (Pui
1997; Rényi 2007; Sánchez Tatay 2010; Wössmann 2003), and
one trial used aggregate participant data from trials of other study
groups as a retrospective analysis (Patte 2002).
The RCT (Goldman 2001) comparing rasburicase with allopuri-
nol included a total of 27 participants in the intervention group
and 25 participants in the control group. This trial included chil-
dren only (aged 0.3 to 17 years) (Goldman 2001). The RCT com-
paring different doses of rasburicase included a total of 15 partic-
ipants in the low-dose group (0.15 mg/kg) and 15 participants in
the high-dose group (0.2 mg/kg) (Kikuchi 2009). This trial also
included children only (aged 0 to 17 years) (Kikuchi 2009). The
five CCTs comparing urate oxidase with allopurinol included a
total of 429 participants in the intervention groups and 563 par-
ticipants in the control groups. All five CCTs included children
only. Two of these trials reported a median age of 4.5 to 5.6 years
in the intervention groups and 5.7 to 6 years in the control groups
(Pui 1997; Rényi 2007). The remaining three trials (Patte 2002;
Sánchez Tatay 2010; Wössmann 2003) did not mention the age
distribution of the participants.
The types of malignancies included in all trials were similar.
The RCT comparing rasburicase and allopurinol recruited par-
ticipants with stage three or four non-Hodgkin’s lymphoma,
acute lymphoblastic leukaemia (ALL) with high WBC counts,
and participants with leukaemia or lymphoma with hyperuri-
caemia (Goldman 2001). The RCT comparing high-dose and
low-dose rasburicase recruited participants with stage four non-
Hodgkin’s lymphoma, stage three non-Hodgkin’s lymphoma with
large lymph node or high LDH, and acute leukaemia with high
WBC counts (Kikuchi 2009). All five CCTs included participants
with haematological malignancies who were at high risk of TLS,
with just minor differences in the inclusion criteria among these
trials (for details, please refer to the Characteristics of included
studies tables).
For outcome measures, only one study reported incidence of
clinical TLS (Wössmann 2003). Five studies (Goldman 2001;
Kikuchi 2009; Rényi 2007; Sánchez Tatay 2010; Wössmann
2003) reported on all-cause mortality. Five studies (Goldman
2001; Kikuchi 2009; Patte 2002; Rényi 2007; Sánchez Tatay
2010) also reported on mortality due to TLS. All seven included
studies reported frequency of renal failure requiring renal replace-
ment therapy (Goldman 2001; Kikuchi 2009; Patte 2002; Pui
1997; Rényi 2007; Sánchez Tatay 2010; Wössmann 2003), two
studies reported frequency of normalisation of serum uric acid
(Goldman 2001; Kikuchi 2009), one study reported AUC of
serum uric acid (Goldman 2001), and four studies reported serial
uric acid levels (Kikuchi 2009; Pui 1997; Rényi 2007; Sánchez
Tatay 2010). Five studies reported adverse events (Goldman 2001;
Kikuchi 2009; Pui 1997; Rényi 2007; Sánchez Tatay 2010).
Excluded studies
We excluded three RCTs evaluating urate oxidase for prevention of
TLS as they recruited adult participants only and did not include
paediatric participants (Cortes 2010; Ishizawa 2009; Vadhan-Raj
2012).
Risk of bias in included studies
In general, none of the included trials were of highmethodological
quality. The two RCTs were quite small, recruiting only 30 to 52
participants (Goldman 2001; Kikuchi 2009).We describe the risk
of bias in the ’Characteristics of included studies’ tables, Figure 2,
and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
Allocation
All five CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay
2010; Wössmann 2003) included in this review were not ran-
domised trials and selection bias was likely present. The RCT
Kikuchi 2009 did not report random sequence generation or con-
cealment. We were uncertain whether there was high risk of selec-
tion bias. Random sequence generation and randomisation con-
cealment were likely to be adequate in Goldman 2001 as the ran-
domisation code was computer-generated.
Blinding
There was no blinding of participants or care providers in all five
included CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay
2010; Wössmann 2003). Also, the two included RCTs (Goldman
2001; Kikuchi 2009) did not blind participants or care providers,
which might have introduced performance bias.
We assessed detection biases for each outcome separately (except
all-causemortality) and they are summarised inFigure 2 andFigure
3. There was no blinding of outcome assessors in all included
RCTs and CCTs and most reported outcomes were considered to
carry high risk of bias. Only the outcome on all-cause mortality
was considered to carry low risk of detection bias as assessment of
death is unlikely to be mistaken or biased, even though outcome
assessors knew which treatment participants were assigned.
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Incomplete outcome data
We assessed attrition biases for each outcome separately and we
have summarised them in Figure 2 and Figure 3. There were drop-
outswith incomplete data in both includedRCTs (Goldman 2001;
Kikuchi 2009). However, dropouts constituted a very low pro-
portion of participants in one study (Kikuchi 2009) and were un-
likely to cause significant attrition bias in the reported outcomes.
Nevertheless, we considered the RCT by Goldman to have a high
risk of bias in the outcomes of renal failure and normalisation of
uric acid as there were differences in the dropout rate between
the intervention and the control groups, and more than 10% of
the participants in the control group had incomplete follow-up
(Goldman 2001). One CCT also had incomplete data for serum
uric acid in a large proportion of participants and we considered
it to have high risk of attrition bias (Rényi 2007). The remaining
four CCTs had no dropouts and we considered them to have low
risk of attrition biases in reported outcomes (Patte 2002; Pui 1997;
Sánchez Tatay 2010; Wössmann 2003).
Selective reporting
It was unclear whether there was selective reporting of outcomes
in all included studies as the trial protocols were not available (
Goldman 2001; Kikuchi 2009; Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003).
Other potential sources of bias
In all studies, there was a high risk of other bias. The interven-
tion and comparison groups were not comparable at baseline in
four studies, which made them at high risk of bias (Goldman
2001; Kikuchi 2009; Rényi 2007; Wössmann 2003). Two studies
(Patte 2002; Sánchez Tatay 2010) did not report some important
baseline characteristics, so the comparability of their intervention
and comparison groups was not certain. For non-randomised con-
trolled trials, failure of adjustment of potential confounders re-
sulted in high risk of bias (Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003). The use of historical con-
trols in four trials (Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003) may have biased the results in favour of the
newer treatment because of improvement in supportive care. In
one CCT (Patte 2002), chemotherapy treatments were different
in different centres in different locations, and this may have caused
bias.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: urate oxidase compared with allopurinol; Summary
of findings 2 Summary of findings: high-dose urate oxidase
compared with low-dose urate oxidase
Urate oxidase versus allopurinol
Six included studies compared urate oxidase with allopurinol for
prevention of TLS. One study was an RCT (Goldman 2001), and
the other five studies were CCTs (Patte 2002; Pui 1997; Rényi
2007; Sánchez Tatay 2010; Wössmann 2003).
Primary outcome
Incidence of clinical TLS
One CCT (Wössmann 2003) that reported this outcome did not
find any significant difference between the group that received
Uricozyme and the group that received allopurinol. (Sixteen out
of 130 participants in the Uricozyme group versus 35 out of 218
participants in the allopurinol group developed TLS; risk ratio
(RR) 0.77, 95% confidence intervals (CI) 0.44 to 1.33; P = 0.34;
intention-to-treat (ITT) analysis; low quality of evidence; Analysis
1.1; Figure 4.) This study also reported results for the subgroup
of participants with acute B lymphoblastic leukaemia (B-ALL)
and found no significant difference between the intervention and
the control groups. (Five out of 53 participants in the Uricozyme
group versus 16 out of 78 participants in the allopurinol group
developed TLS; RR 0.46, 95% CI 0.18 to 1.18; P = 0.11; ITT
analysis; Analysis 1.2).
Figure 4. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.1 Incidence of
clinical tumour lysis syndrome
15Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secondary outcomes
Incidence of laboratory TLS
None of the included trials reported this outcome.
All-cause mortality
The RCT (Goldman 2001) showed slightly lower mortality in the
group that received rasburicase compared with the group that re-
ceived allopurinol, but this was not statistically significant. (None
of the 27 participants in the rasburicase group versus 2 out of 25
participants in the allopurinol group died; Fisher’s exact test P =
0.23; ITT analysis). The two participants in the allopurinol group
died from Pseudomonas sepsis and intracerebral haemorrhage, re-
spectively. All-cause mortality was available in three CCTs, two
of which did not have any mortality (Rényi 2007; Sánchez Tatay
2010), and the third one reported four deaths in the control group
(Wössmann 2003). The study reported the deaths to be treatment-
related, but did not specify the actual cause. The pooled result of
the three CCTs showed no significant difference in all-cause mor-
tality between the intervention and the control groups. (None of
the 158 participants in the urate oxidase group versus 4 out of 248
participants in the allopurinol group died; RR 0.19, 95% CI 0.01
to 3.42; P = 0.26; ITT analysis; Analysis 1.3).
Mortality due to TLS
The RCT (Goldman 2001) did not find any mortality due to
TLS in either the intervention group (total of 27 participants) or
control group (total of 25 participants) (ITT analysis). However,
pooled results of three CCTs (Patte 2002; Rényi 2007; Sánchez
Tatay 2010) showed a significantly lower mortality due to TLS
in the group that received Uricozyme compared with the group
that received allopurinol. (None of the 180 participants in the
intervention group versus 11 out of 216 participants in the control
group died due to TLS; RR 0.05, 95% CI 0.00 to 0.89; P = 0.04;
ITT analysis; low quality of evidence; Analysis 1.4; Figure 5).
Figure 5. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.4 Mortality
due to tumour lysis syndrome
Renal failure requiring renal replacement therapy
TheRCT (Goldman 2001) showed no significant difference in the
frequency of renal failure between the intervention and the con-
trol groups. (None of the 26 participants in the rasburicase group
versus 1 out of 22 participants in the allopurinol group had renal
failure; Fisher’s exact test P = 0.46; not ITT analysis.) In contrast,
pooled results of five CCTs (Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010;Wössmann 2003) showed significantly lower
frequency of renal failure requiring renal replacement therapy in
participants who received urate oxidase compared with those who
received allopurinol. (Twelve out of 429 participants in the in-
tervention group versus 65 out of 563 participants in the control
group developed renal failure; I² = 62%; RR 0.26, 95%CI 0.08 to
0.89; P = 0.03; ITT analysis; very low quality of evidence; Analysis
1.5; Figure 6.) One CCT (Wössmann 2003) reported results of a
subgroup of participants with B-ALL and showed lower frequency
of renal failure in the intervention group, but the difference was
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not statistically significant. (Two out of 53 participants in the in-
tervention group versus 12 out of 78 participants in the control
group developed renal failure; RR 0.25, 95% CI 0.06 to 1.05; P
= 0.06; ITT analysis; Analysis 1.6).
Figure 6. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.5 Renal failure
requiring renal replacement therapy
Normalisation of uric acid level
The RCT (Goldman 2001) showed significantly higher frequency
of uric acid normalisation at four hours in the participants who
received rasburicase compared with participants who received al-
lopurinol. (Ten out of 10 participants in the intervention group
versus zero out of nine participants in the control group had nor-
malisation of uric acid level; Fisher’s exact test P < 0.001; not ITT
analysis; low quality of evidence).
Duration before normalisation of serum uric acid level
None of the included trials reported this outcome.
Area under the curve (AUC) of serum uric acid level
The RCT (Goldman 2001) reported a significantly lower AUC
of serum uric acid at four days in the intervention group com-
pared with the control group (mean AUC 128 mg/dLhr in 27
participants in the intervention group versus 329 mg/dLhr in 25
participants in the control group; mean difference (MD) -201.00
mg/dLhr, 95% CI -258.05 mg/dLhr to -143.95 mg/dLhr; P <
0.00001; ITT analysis; low quality of evidence; Analysis 1.7.) The
RCT also reported results of different subgroups and found sig-
nificantly lower AUC of serum uric acid at four days in the inter-
vention group compared with the control group in participants
with leukaemia (mean AUC 141 mg/dLhr in 20 participants in
the intervention group versus 361 mg/dLhr in 19 participants in
the control group; MD -220.00 mg/dLhr, 95% CI -286.67 mg/
dLhr to -153.33 mg/dLhr; P < 0.00001; ITT analysis; Analysis
1.8), lymphoma (mean AUC 92 mg/dLhr in seven participants in
the intervention group versus 224 mg/dLhr in six participants in
the control group; MD -132.00 mg/dLhr, 95% CI -185.47 mg/
dLhr to -78.53mg/dLhr; P < 0.00001; ITT analysis; Analysis 1.9),
baseline hyperuricaemia participants (mean AUC 162 mg/dLhr
in 10 participants in the intervention group versus 440 mg/dLhr
in nine participants in the control group; MD -278.00 mg/dLhr,
95% CI -373.69 mg/dLhr to -182.31 mg/dLhr; P < 0.00001;
ITT analysis; Analysis 1.10), and participants with normal base-
line uric acid (mean AUC 108 mg/dLhr in 17 participants in the
intervention group versus 348 mg/dLhr in 16 participants in the
control group; MD -240.00 mg/dLhr, 95% CI -340.95 mg/dLhr
to -139.05 mg/dLhr, P < 0.00001; ITT analysis; Analysis 1.11).
Serial uric acid level
Three CCTs reported serial uric acid levels (Pui 1997; Rényi
2007; Sánchez Tatay 2010). All three CCTs reported results on the
first two days after urate oxidase, while two studies (Rényi 2007;
SánchezTatay 2010) reported results up to four days and one study
(Rényi 2007) reported results up to 12 days. The pooled results
showed significantly lower uric acid level in the intervention group
compared with the control group at two days (mean uric acid level
1.02mg/dL in 147 participants the intervention group versus 3.25
mg/dL in 147 participants in the control group; I² = 87%; MD
-3.80 mg/dL, 95% CI -7.37 mg/dL to -0.24 mg/dL; P = 0.04;
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not ITT analysis; < 70% of participants had outcomes available
for Rényi 2007; results susceptible to bias; Analysis 1.12), three
days (mean uric acid level 0.52 mg/dL in 28 participants in the
intervention group versus 4.66 mg/dL in 19 participants in the
control group; I² = 89%; MD -3.13 mg/dL, 95% CI -6.12 mg/dL
to -0.14 mg/dL; P = 0.04; not ITT analysis; < 70% of participants
had outcomes available for Rényi 2007; results susceptible to bias;
Analysis 1.13), four days (mean uric acid level 0.24 mg/dL in
28 participants in the intervention group versus 4.41 mg/dL in
17 participants in the control group; MD -4.60 mg/dL, 95% CI
-6.39 mg/dL to -2.81 mg/dL; P < 0.00001; not ITT analysis;
< 70% of participants had outcomes available for Rényi 2007;
results susceptible to bias; Analysis 1.14), and seven days (mean
uric acid level 1.43 mg/dL in 12 participants in the intervention
group versus 3.17 mg/dL in four participants in the control group;
MD -1.74 mg/dL, 95% CI -3.01 mg/dL to -0.47 mg/dL; P =
0.007; not ITT analysis; < 70% of participants had outcomes
available for Rényi 2007; results susceptible to bias; Analysis 1.15),
but not significant at one day (mean uric acid level 1.37 mg/dL
in 147 participants in the intervention group versus 3.94 mg/dL
in 151 participants in the control group; I² = 94%; MD -3.00
mg/dL, 95% CI -7.61 mg/dL to 1.60 mg/dL; P = 0.2; not ITT
analysis; < 70% of participants had outcomes available for Rényi
2007; results susceptible to bias; Analysis 1.16), five days (mean
uric acid level 0.44 mg/dL in 12 participants in the intervention
group versus 1.46 mg/dL in two participants in the control group;
MD -1.02 mg/dL, 95% CI -2.24 mg/dL to 0.20 mg/dL; P = 0.1;
not ITT analysis; < 70% of participants had outcomes available
for Rényi 2007; results susceptible to bias; Analysis 1.17), and 12
days (mean uric acid level 2.34 mg/dL in 12 participants in the
intervention group versus 3.14 mg/dL in eight participants in the
control group; MD -0.80 mg/dL, 95% CI -2.51 mg/dL to 0.91
mg/dL; P = 0.36; not ITT analysis; Analysis 1.18).
Adverse events
The RCT (Goldman 2001) and three CCTs (Pui 1997; Rényi
2007; Sánchez Tatay 2010) reported frequency of adverse effects
in the intervention and control groups. The RCT showed no
significant differences between the intervention and the control
groups. (One out of 27 participants in the intervention group ver-
sus none of the 25 participants in the control group had an ad-
verse event; Fisher’s exact test P = 1.0; ITT analysis.) The adverse
event reported was haemolysis. The pooled results from CCTs
showed significantly higher frequency of adverse effects in partic-
ipants who received urate oxidase. (Thirteen out of 186 partic-
ipants in the intervention group versus none of the 159 partic-
ipants in the control group had adverse events; RR 9.10, 95%
CI 1.29 to 64.00; P = 0.03; I² = 0%; ITT analysis; low qual-
ity of evidence; Analysis 1.19.) Adverse events reported in the
intervention group included allergic reaction (six participants),
methaemoglobinaemia (one participant), fever (two participants),
nausea (one participant), abdominal pain (one participant), and
mucositis (two participants). It should be noted that the Pui 1997
and Rényi 2007 studies included additional participants in this
analysis (see the Characteristics of included studies tables for more
information).
High-dose urate oxidase versus low-dose urate
oxidase
One RCT (Kikuchi 2009) compared urate oxidase (rasburicase)
given in high dose (0.2 mg/kg/day for five days) versus low dose
(0.15 mg/kg/day for five days).
Primary outcome
Incidence of clinical TLS
The RCT did not report this outcome.
Secondary outcomes
Incidence of laboratory TLS
The RCT did not report this outcome.
All-cause mortality
The RCT (Kikuchi 2009) reported no significant difference in all-
cause mortality between the high-dose and the low-dose groups.
(None of the 15 participants in the high-dose group versus one of
the 15 participants in the low-dose group died; Fisher’s exact test
P = 1.0; ITT analysis.) The death in the low-dose group was due
to cerebral haemorrhage, brain oedema, and brain herniation.
Mortality due to TLS
The RCT (Kikuchi 2009) reported no mortality due to TLS in
both the high-dose group (15 participants) and the low-dose group
(15 participants) (ITT analysis; low quality of evidence).
Renal failure requiring renal replacement therapy
The RCT (Kikuchi 2009) reported no renal failure due to TLS in
both the high-dose group (14 participants) and the low-dose group
(15 participants) (not ITT analysis; low quality of evidence).
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Normalisation of uric acid level
The RCT (Kikuchi 2009) showed no significant difference be-
tween the high-dose and the low-dose groups. (All participants
(14) in the high-dose group versus 14 out of 15 participants in
the low-dose group had normalisation of uric acid level; RR 1.07,
95% CI 0.89 to 1.28; P = 0.49; not ITT analysis; low quality of
evidence; Analysis 2.1).
Duration before normalisation of serum uric acid level
The included RCT did not report this outcome.
AUC of serum uric acid level
The included RCT did not report this outcome.
Serial uric acid level
The RCT (Kikuchi 2009) reported the percentage reduction of
uric acid level at four hours and did not find any significant differ-
ence between the high-dose and the low-dose groups (mean per-
centage reduction in uric acid level 92.9% in 14 participants in
the high-dose group versus 84.8% in 15 participants in the low-
dose group; MD 8.10%, 95% CI -0.99% to 17.19%; P = 0.08;
not ITT analysis; low quality of evidence; Analysis 2.2).
Adverse events
The RCT (Kikuchi 2009) did not show any significant difference
in the frequency of adverse events between the high-dose group
(two out of 14 participants) and the low-dose groups (four out
of 15 participants) (RR 0.54, 95% CI 0.12 to 2.48; P = 0.42;
not ITT analysis; low quality of evidence; Analysis 2.3). Adverse
events included allergic reaction (three participants), haemolysis
(one participant), and anaemia (two participants).
Sensitivity analysis and cost-benefit analysis
We planned to do sensitivity analysis for heterogeneous results by
excluding outlying results. We could not identify any obvious out-
liers, and therefore did not perform this sensitivity analysis. Since
there was only one RCT with adequate allocation concealment,
which we did not include in a pooled analysis, we did not perform
sensitivity analysis for this. Since we identified no high-quality
data on effectiveness, we did not perform a cost-benefit analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High-dose urate oxidase compared with low-dose urate oxidase for prevention of tumour lysis syndrome
Patient or population: children with haematological malignancy at risk of tumour lysis syndrome
Settings: hospital inpatient
Intervention: high-dose urate oxidase
Comparison: low-dose urate oxidase
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Low-dose urate oxi-
dase
High-dose urate oxi-
dase
Incidence of clinical tu-
mour lysis syndrome
Not reported Not reported Not applicable Not applicable Not applicable None of the studies re-
ported on this outcome
measure
Mortality due to tumour
lysis syndrome
0 per 1000 0 per 1000a Not applicable 30
(1)
⊕⊕©©
lowb
None of part icipants
died in both the inter-
vent ion and the control
groups
Renal failure requir-
ing renal replacement
therapy
0 per 1000 0 per 1000a Not applicable 29
(1)
⊕⊕©©
lowb
None of part icipants
had renal failure in ei-
ther the intervent ion or
the control groups
Normalisation of
serum uric acid
(follow-up: 5 weeks)
933 per 1000 998 per 1000
(830 to 1000)
RR 1.07 (0.89 to 1.28) 29
(1)
⊕⊕©©
lowb
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Percentage reduction
in serum uric acid level
at 4 hours
(follow-up: 4 hours)
The mean percentage
reduct ion in serum uric
acid level at 4 hours in
the control group was
84.8%.
The mean percentage
reduct ion in serum uric
acid level at 4 hours in
the intervent ion group
was
8.1% higher (0.99%
lower to 17.19%higher)
29
(1)
⊕⊕©©
lowb
AUC of serum uric acid
level
Not reported Not reported Not applicable Not applicable Not applicable None of the studies re-
ported on this outcome
measure
Frequency of adverse
events
(follow-up: 5 weeks)
267 per 1000 144 per 1000
(32 to 662)
RR 0.54 (0.12 to 2.48) 29
(1)
⊕⊕©©
lowb
* The basis for the assumed risk is the control group risk in the included study. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
AUC: area under the curve; CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aSince control group risk (assumed risk) is zero, corresponding risk est imation is based on risk in the intervent ion group in
the included study.
bEvidence f rom RCT downgraded by two levels because of high risk of bias in study design and imprecise result .
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D I S C U S S I O N
Summary of main results
This is the second update of the original systematic review. No
new studies were included and conclusions did not change. Al-
though numerous uncontrolled studies have found that urate ox-
idase can lower serum uric acid levels quickly and sometimes dra-
matically, we found little evidence from randomised controlled
trials (RCTs) or controlled clinical trials (CCTs) supporting its ef-
fectiveness in preventing or treating tumour lysis syndrome (TLS)
in children with cancer. Only two RCTs (Goldman 2001; Kikuchi
2009) and five CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez
Tatay 2010; Wössmann 2003) were available on the prophylaxis
of tumour lysis syndrome. There is currently no trial evaluating
urate oxidase for treatment of established TLS.
Urate oxidase versus allopurinol
Six included studies compared urate oxidase with allopurinol for
the prevention of tumour lysis syndrome. One study was an RCT
(Goldman 2001), and the other five studies were CCTs (Patte
2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010; Wössmann
2003). One CCT (Wössmann 2003) reported the incidence of
clinical TLS and did not find significant difference between the
group that received Uricozyme and the group that received allop-
urinol. The RCT (Goldman 2001) showed no significant differ-
ence in all-cause mortality between the group that received ras-
buricase and the group that received allopurinol. The pooled result
of the three CCTs (Rényi 2007; Sánchez Tatay 2010; Wössmann
2003) also showed no significant difference in all-cause mortal-
ity between the intervention and the control groups. The RCT
(Goldman 2001) did not find any mortality due to TLS in ei-
ther the intervention group or the control group. However, the
pooled result of the three CCTs (Patte 2002; Rényi 2007; Sánchez
Tatay 2010) showed a significantly lower mortality due to TLS
in the group that received Uricozyme compared with the group
that received allopurinol. The RCT (Goldman 2001) showed no
significant difference in the frequency of renal failure between the
intervention and the control groups. In contrast, pooled results
of five CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay
2010; Wössmann 2003) showed significantly lower frequency of
renal failure requiring renal replacement therapy in participants
who received urate oxidase compared with those who received al-
lopurinol. However, heterogeneity was present in this analysis.
The RCT (Goldman 2001) showed significantly higher frequency
of uric acid normalisation at four hours in the participants who
received rasburicase compared with participants who received al-
lopurinol. All included trials did not report the duration before
normalisation of serum uric acid level. The RCT (Goldman 2001)
reported a significantly lower AUC of serum uric acid at four
days in the intervention group compared with the control group.
Three CCTs reported serial uric acid levels (Pui 1997; Rényi 2007;
Sánchez Tatay 2010). All three CCTs reported results on the
first two days after urate oxidase, while two studies (Rényi 2007;
Sánchez Tatay 2010) reported results up to four days, and one
study (Rényi 2007) reported results up to 12 days. The pooled
results showed significantly lower uric acid levels in the interven-
tion group compared with the control group at two days, three
days, four days, and seven days, but the differences were not sig-
nificant at one day, five days, and 12 days. Heterogeneity was
present in some of these analyses. The RCT (Goldman 2001)
and three CCTs (Pui 1997; Rényi 2007; Sánchez Tatay 2010)
reported frequency of adverse effects in the intervention and the
control groups. The RCT showed no significant differences be-
tween the intervention and the control groups. The adverse event
reported was haemolysis. The pooled results from the three CCTs
showed significantly higher frequency of adverse effects in partic-
ipants who received urate oxidase. Adverse events reported in the
intervention group included allergic reaction (six participants),
methaemoglobinaemia (one participant), fever (two participants),
nausea (one participant), abdominal pain (one participant), and
mucositis (two participants).
High-dose versus low-dose urate oxidase
We included one RCT that compared high-dose versus low-dose
rasburicase (Kikuchi 2009). The trial did not report the incidence
of TLS. The trial reported no significant difference in all-cause
mortality between the high-dose and the low-dose groups. There
was no mortality due to TLS in both the high-dose and the low-
dose groups. There was no renal failure due to TLS in both groups.
There was no significant difference in normalisation of uric acid
level between the high-dose and the low-dose groups. The included
RCT did not report the duration before normalisation of serum
uric acid level or the AUC of serum uric acid level. The trial
reported the percentage reduction of uric acid level at four hours
and did not find significant difference between the two groups.
There was no significant difference in the frequency of adverse
events between the two groups. Adverse events included allergic
reaction (three participants), haemolysis (one participant), and
anaemia (two participants).
Overall completeness and applicability of
evidence
Although urate oxidase is widely used in children with cancer for
prevention of TLS, high-quality evidence of its efficacy is lim-
ited. The only RCT comparing urate oxidase with allopurinol
(Goldman 2001) did not report the important outcome of clinical
TLS. Although participants who received rasburicase had signifi-
cantly lower exposure to uric acid (lower AUC and higher chance
of uric acid normalisation) compared with participants who re-
ceived allopurinol in the RCT (Goldman 2001), we were not en-
tirely certain whether this translated into significant clinical ben-
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efits. Although hyperuricaemia is related to TLS, this trial failed
to show any significant difference between the treatment and the
control groups in all-cause mortality or mortality related to TLS
or renal failure requiring renal replacement therapy. Because of
the paucity of evidence from RCTs, we also included CCTs in the
current systematic review. However, all five CCTs identified were
of unsatisfactory methodological quality. Although mortality due
to TLS and incidence of renal failure were found to be significantly
lower in participants who received urate oxidase, the conclusion
from CCTs has to be treated with caution in view of high risk of
biases.
On the other hand, due to inadequate sample size in the existing
trials, the absence of significant clinical benefits of urate oxidase
may be a false negative result. Therefore, we cannot ignore the
potential benefits of urate oxidase in children with malignancy
based on the current available evidence, especially in view of its
probable effectiveness in reducing serum uric acid, which is an
important surrogate outcome. Further trials of larger sample size
are needed to clarify the role of urate oxidase. Assuming amortality
rate of 0.9% (Annemans 2003a) and that urate oxidase is effective
in reducing mortality by half, the number of people with cancer
needed to treat to prevent one death is 223, and the sample size
required to achieve a power of 80% in detecting a reduction in
mortality at a 5% level of significance is estimated to be 856 people.
There was only one RCT comparing different doses of rasburicase
(Kikuchi 2009). The results were consistent with previous uncon-
trolled studies and CCTs; comparing rasburicase at 0.15 mg/kg
and 0.2 mg/kg showed a dramatic reduction in serum uric acid
level in both arms. However, the RCT did not report the impor-
tant outcome of incidence of clinical TLS, and this small trial was
not adequately powered to address the other clinically important
outcomes of mortality or renal failure. Although there was no sig-
nificant difference in any of the outcomes between the two groups,
we are not certain whether a higher and lower dose of rasburicase
are really equivalent because of the small sample size. Likewise,
there is uncertainly about whether the higher dose is associated
with more adverse effects.
Although not eligible for inclusion in this review, there is a study
that has addressed the cost-effectiveness of rasburicase (Annemans
2003b). This study concluded that rasburicase was cost-effective
for prevention of TLS in children, and rasburicase for the treat-
ment of TLS in children was cost-saving. However, this conclu-
sion was based on the assumption that rasburicase is 60% to 100%
effective in the prevention of TLS, which was not in fact based on
high-quality trial evidence. As the effectiveness of urate oxidase in
the prevention or treatment of TLS has yet to be established, its
cost-effectiveness remains uncertain.
Quality of the evidence
Apart from limitations in the number of RCTs reporting clini-
cally relevant outcomes and inadequate power to evaluate these
outcomes, the trials included in the current review had a number
of methodological flaws and were prone to bias. We considered
none of the included studies to have low risk of bias in all aspects
assessed. In both RCTs, the treatment and the control groups were
not comparable at baseline, which cast doubt on the success of
randomisation and increased the probability of confounding. One
of the RCTs included did not report the random sequence genera-
tion or allocation concealment, which are important to minimise
selection bias (Kikuchi 2009). The other RCT had more drop-
outs in the control arm than in the treatment arm, which might
have caused attrition bias (Goldman 2001). None of the included
RCTs attempted to blind the participants, physicians, or outcome
assessors, which might have introduced performance and detec-
tion biases. Trial protocols were not available, and it was uncertain
whether there was reporting bias in the RCTs.
In addition, all five CCTs included were also of unsatisfac-
tory methodological quality (Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003). There was a high risk of
selection bias as participants were not randomly allocated to treat-
ment groups. Performance and detection biases were also likely as
there was no blinding. Reporting bias was uncertain as trial proto-
cols were not available. There was a high risk of attrition bas in one
CCT, which had a lot of missing data (Rényi 2007). The results
from the four historical controlled trials (Pui 1997; Rényi 2007;
SánchezTatay 2010;Wössmann 2003)were prone to bias from the
advancement of supportive care with time. The remaining CCT
(Patte 2002) was actually a retrospective review of data from trials
of chemotherapy protocols comparing different treatments from
different study groups at different locations; therefore, it suffered
from bias due to different practices in different centres. The inter-
vention and comparison groups were not comparable at baseline
in two studies, whichmight result in high risk of bias (Rényi 2007;
Wössmann 2003). Two studies (Patte 2002; Sánchez Tatay 2010)
did not report some important baseline characteristics, so compa-
rability of the intervention and comparison groups was uncertain.
None of the included CCTs took into consideration and adjusted
for potential confounding factors in their analyses; hence, their
results were susceptible to confounding by known and unknown
factors.
In conclusion, the quality of evidence for the use of urate oxidase
for prevention of TLS in children with cancer ranks from very low
to low, because of high risk of bias in existing trials and imprecise
results.
Potential biases in the review process
We focused our search on major English language electronic
databases; therefore, non-English literature might be under-rep-
resented and missed in the review. Because the search was focused
on RCTs and CCTs, we could have missed some further historical
controlled trials. Publication bias was also possible.
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Agreements and disagreements with other
studies or reviews
As far as we know, this is the only systematic review evaluating
the effectiveness of urate oxidase for prevention and treatment of
TLS in children with cancer. There was a review on TLS with
targeted therapy and the role of rasburicase (Bose 2011). The au-
thors performed a search onMEDLINE in February 2011 and in-
cluded RCTs, CCTs, and single-arm studies of rasburicase in both
children and adults. That review had a similar conclusion to the
current review, that although there was a wealth of evidence sug-
gesting that rasburicase is effective in correcting hyperuricaemia,
prospective trials showing that it improves hard outcomes, such
as acute renal failure, need for dialysis, and mortality, are lacking.
More randomised controlled trials evaluating clinically relevant
outcomes are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Thus far, the paucity of high-quality studies precludes firm rec-
ommendations. Although there is some low-quality evidence that
urate oxidase might be more effective than allopurinol in reducing
the frequency of hyperuricaemia and the exposure to high serum
uric acid, it is still uncertain whether the routine use of urate ox-
idase is effective for the prevention or treatment of tumour lysis
syndrome (TLS), or a reduction in mortality or renal failure asso-
ciated with TLS in children with cancer. The potential benefit of
urate oxidasemight be its effectiveness in reducing serumuric acid,
which is an important surrogate outcome. It is unclear which type
of urate oxidase (rasburicase or Uricozyme) is superior in terms
of efficacy and what dosage regimen or treatment duration is op-
timal. On the other hand, urate oxidase may be associated with
potential adverse effects, such as haemolysis or hypersensitivity.
Clinicians who wish to use urate oxidase should weigh the poten-
tial benefits of reducing serum uric acid levels and the uncertain
benefits in preventing renal failure or mortality from TLS against
the potential risk of adverse effects.
Implications for research
There is a paucity of evidence from randomised controlled trials
(RCT) assessing urate oxidase for the prevention and treatment
of TLS in children with cancer. The existing trials are of small
size and lowmethodological quality. Further high-quality RCTs of
larger sample size are needed to assess the effectiveness of urate ox-
idase in children, especially high-risk patients who are more likely
to benefit. High-risk patients can include those with high tumour
burden or turn-over (such as high initial white blood cell counts
for leukaemia, or Burkitt lymphoma, high-stage lymphoma, or
lymphoma with bulky disease), and people with baseline hy-
peruricaemia, renal impairment, hypocalcaemia, or hypophos-
phataemia. Trials should assess patient-orientated outcomes, such
as incidence of clinical TLS, mortality, or frequency of renal fail-
ure. Although blinding of participants and clinicians for compar-
ison of intravenous urate oxidase and oral allopurinol is difficult,
it can be attempted with the use of a double placebo, to minimise
performance biases. The effectiveness and safety of different forms
of urate oxidase in different dosage regimens should also be inves-
tigated further.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Goldman 2001
Methods Design: RCT
Randomisation method: stratified randomisation, computer-generated randomisation
code
Stratification factor: according to uric acid level (< 8 mg/dL or ≥ 8 mg/dL)
Participants Inclusion criteria: paediatric participants < 18 years with leukaemia and lymphoma
deemed to have a high risk of tumour lysis syndrome: Murphy stage III or IV non-
Hodgkin’s lymphoma,ALLwithWBC≥ 25,000/uL, childhood lymphomaor leukaemia
with uric acid level of ≥ 8 mg/dL. Participants must have received chemotherapeutic
agents not investigational in nature, with minimum life expectancy of 4 weeks, and
ECOG performance scale ≤ 3 or Karnofsky scale ≥ 30%
Exclusion criteria: participants previously treated with rasburicase or Uricozyme, treat-
ment with allopurinol within 7 days, significant history of documented asthma, atopy,
or G6PD deficiency
Number of participants (intervention/comparison): 27/25
Number of boys (intervention/comparison): 16/18
Age (intervention/comparison): (mean) 7.1 (range = 0.3 to 17)/7.8 (range = 0.5 to 16)
years
Underlying haematological malignancies (intervention/comparison): leukaemia 20/9;
lymphoma 7/6
Baseline creatinine (intervention/comparison): (mean) 0.6 (SD 0.33)/0.61 (SD 0.3) mg/
dL
Baseline uric acid (intervention/comparison): (mean) 7.7 (SD 3.5)/6.8 (SD 3.4) mg/dL
Baseline potassium (intervention/comparison): (mean) 4.18 (SD 0.71)/3.85 (SD 0.52)
mg/dL
Baseline phosphate (intervention/comparison): (mean) 4.62 (SD 1.39)/4.15 (SD 1.11)
mg/dL
Baseline calcium (intervention/comparison): (mean) 8.92 (SD 0.74)/8.67 (SD 0.7) mg/
dL
Baseline LDH (intervention/comparison): (mean) 1599 (SD 1022)/1393 (SD 1438) U/
L
Baseline WBC (intervention/comparison): (mean) 83.2 (SD 81)/91 (SD 115) x 109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 min daily for
5-7 days
Treatment regime in comparison group: allopurinol 300mg/m²/d or 10mg/kg/d divided
every 8 h for 5-7 days
Cointerventions: hydration 3 L/m²/d, iv sodium bicarbonate at investigator’s discretion
Outcomes • All-cause mortality
• Mortality due to TLS
• Incidence of renal failure requiring renal replacement therapy
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Goldman 2001 (Continued)
• Frequency of normalisation of serum uric acid level
• Area under the curve (AUC) of serum uric acid level
• Frequency of adverse effects (haemolysis)
Notes Duration of follow up: 2 weeks
Number of dropouts (intervention/comparison): 1 (haemolysis)/3 (2 died; 1 did not
start chemotherapy)
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because serum uric acid level was higher
in the treatment group
Whether outcomes were clearly defined: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...treatment (rasburicase or allop-
urinol) was randomly allocated to patients
according to a computer-generated ran-
domization code schema”
Allocation concealment (selection bias) Low risk Quote: “Via telephone entry, treatment
(rasburicase or allopurinol) was randomly
allocated to patients according to a
computer-generated randomization code
schema”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants knew which treatment they
were allocated, and care providers knew
which treatment a participant was allocated
Blinding of outcome assessment (detection
bias)
All-cause mortality
Low risk Assessment of death is unlikely to be mis-
taken or biased, even though outcome as-
sessors knew which treatment participants
were assigned
Blinding of outcome assessment (detection
bias)
Mortality due to tumour lysis syndrome
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Normalisation of uric acid level
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
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Goldman 2001 (Continued)
Blinding of outcome assessment (detection
bias)
Area under curve (AUC) of serum uric acid
level
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Incomplete outcome data (attrition bias)
All-cause mortality
Low risk This outcome was reported for all partici-
pants
Incomplete outcome data (attrition bias)
Mortality due to tumour lysis syndrome
Low risk This outcome was reported for all partici-
pants
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
High risk 4% of participants in the treatment group
and 12% of participants in the control
group did not complete treatment or follow
up and outcome was not certain for them
Incomplete outcome data (attrition bias)
Normalisation of uric acid level
High risk Only a subset of randomised participants
(37% of the treatment group and 36% of
the control group) who had baseline hype-
ruricaemia were analysed and reported
Incomplete outcome data (attrition bias)
Area under curve (AUC) of serum uric acid
level
Low risk This outcome was reported for all partici-
pants
Incomplete outcome data (attrition bias)
Adverse events
Low risk This outcome was reported for all partici-
pants
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because serum uric acid level was
higher in the treatment group,whichmight
introduce bias
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Kikuchi 2009
Methods Design: RCT
Randomisation method: central randomisation, details not available
Stratification factor: baseline body weight (< 10 or ≥ 10 kg)
Participants Inclusion criteria: paediatric participants < 18 years with newly diagnosed haematological
malignancies with hyperuricaemia (uric acid > 7.5 mg/dL for participants ≥ 13 years;
uric acid > 6.5 mg/dL for participants < 13 years) or with a high tumour burden (defined
as non-Hodgkin’s lymphoma stage IV; NHL stage III with ≥ 1 lymph node or mass >
5 cm, or LDH ≥ 3 times the upper limit of normal) or acute leukaemia with WBC ≥
50,000/mm³ and LDH ≥ 3 times the upper limit of normal
ECOG performance scale ≤ 3 or Lansky score ≥ 30
Life expectancy ≥ 45 days
Exclusion criteria: administration of allopurinol within 72 h; known history of severe
allergy, severe asthma, or both; low birth weight (< 2500 g) or gestational age < 37 weeks;
previous therapy with urate oxidase; positive HBsAg, HCV antibodies, HIV-1 or HIV-
2 antibodies; severe disorders of the liver or kidney (ALT > 5 times the upper limit of
normal, total bilirubin > 3 times the upper limit of normal; creatinine > 3 times the upper
limit of normal); uncontrollable infection including viral infection; G6PD deficiency;
known family history of G6PD deficiency; known history of methaemoglobinaemia and
haemolysis
Number of participants (low-dose group/high-dose group): 15/15
Number of boys (low-dose group/high-dose group): 9/10
Age (low-dose group/high-dose group): (median) 11 (range = 1-17)/7 (range = 0-16)
years
Underlying haematological malignancies (low-dose group/high-dose group): acute
leukaemia 9/13; lymphoma 6/2
Baseline hyperuricaemia (low-dose group/high-dose group): 8/5
Baseline creatinine (low-dose group/high-dose group): (mean) 52.3 (SD 22.6)/44.4 (SD
19.1) mg/dL
Interventions Intervention (type of urate oxidase): rasburicase in both groups (0.15 mg/kg versus 0.2
mg/kg)
Treatment regime in low-dose group: rasburicase 0.15 mg/kg ivi over 30 min daily for 5
d
Treatment regime in high-dose group: rasburicase 0.2 mg/kg ivi over 30 min daily for 5
d
Cointerventions: chemotherapy started 4-24 h after the first dose of rasburicase in both
groups
Outcomes • All-cause mortality
• Mortality due to TLS
• Incidence of renal failure requiring renal replacement therapy
• Frequency of normalisation of serum uric acid level
• Serial uric acid levels
• Frequency of adverse events
Notes Duration of follow up: 5 weeks
Number of dropouts (low-dose group/high-dose group): 1 (3 concomitant grade 4 ad-
verse events)/1 (lack of WBC result at baseline)
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Kikuchi 2009 (Continued)
The 2 groups may not be comparable at baseline because body weight was higher in
the low-dose group; baseline hyperuricaemia and diagnosis of lymphoma were more
frequent in the low-dose group
Whether outcomes were clearly defined: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocated to the
2 treatment groups by central randomisa-
tion, but details were not available
Allocation concealment (selection bias) Unclear risk This was not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants knew which treatment they
were allocated, and care providers knew
which treatment a participant was allocated
Blinding of outcome assessment (detection
bias)
All-cause mortality
Low risk Assessment of death is unlikely to be mis-
taken or biased, even though outcome as-
sessors knew which treatment participants
were assigned
Blinding of outcome assessment (detection
bias)
Mortality due to tumour lysis syndrome
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Normalisation of uric acid level
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Serial uric acid level
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Incomplete outcome data (attrition bias)
All-cause mortality
Low risk This outcome was reported for all partici-
pants
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Kikuchi 2009 (Continued)
Incomplete outcome data (attrition bias)
Mortality due to tumour lysis syndrome
Low risk This outcome was reported for all partici-
pants
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk 6.7%of participants in the high-dose group
did not complete treatment and this out-
come for not reported. The dropout was
explained. The low proportion of dropout
is unlikely to cause significant bias
Incomplete outcome data (attrition bias)
Normalisation of uric acid level
Low risk 6.7%of participants in the high-dose group
did not complete treatment and this out-
come for not reported. The dropout was
explained. The low proportion of dropout
is unlikely to cause significant bias
Incomplete outcome data (attrition bias)
Serial uric acid level
Low risk 6.7%of participants in the high-dose group
did not complete treatment and this out-
come for not reported. The dropout was
explained. The low proportion of dropout
is unlikely to cause significant bias
Incomplete outcome data (attrition bias)
Adverse events
Low risk 6.7%of participants in the high-dose group
did not complete treatment and this out-
come for not reported. The dropout was
explained. The low proportion of dropout
is unlikely to cause significant bias
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because body weight was higher
in the low-dose group; baseline hyperuri-
caemia and diagnosis of lymphoma were
more frequent in the low-dose group
Patte 2002
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with stage III and IV B-cell NHL or L3 ALL
treated with the LMB89 protocol (intervention group), paediatric participants with
stage IV B-cell NHL or ALL treated with UKCCSG protocol (comparison group 1),
or paediatric participants with stage IV B-cell NHL or ALL treated with POG protocol
(comparison group 2)
Exclusion criteria: participants not treated in France excluded from intervention group
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Patte 2002 (Continued)
Number of participants (intervention/comparison 1/comparison 2): 152/63/123
Number of boys (intervention/comparison 1/comparison 2): not available
Age (intervention/comparison 1/comparison 2): not available
Underlying haematological malignancies: only data for intervention group available: B-
NHL stage III 257 out of 410; B-NHL stage IV 57 out of 410; L3 ALL 96 out of 410
Baseline renal failure (intervention/comparison 1/comparison 2): 21/410/not available
Baseline elevated LDH ≥ 2 x normal (intervention/comparison 1/comparison 2): 234/
410/not available
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison 1 and 2 (type of control): allopurinol
Treatment regime in intervention group: Uricozyme 50-100 U/kg/d for 5-7 d
Treatment regime in comparison groups: not available
Cointerventions: intervention group: alkaline hyperhydration 3 L/m²/d to obtain urine
output 100-120 ml/m²/h and urine pH 7; not stated in comparison groups
Outcomes • Mortality due to TLS
• Incidence of renal failure requiring renal replacement therapy
Notes Duration of follow up: 7 d
Number of dropouts (intervention/comparison 1/comparison 2): 0/0/0
Potential confounders were not described or adjusted
Comparability of the treatment groups at baseline was uncertain because some important
baseline characteristics of comparison groups were not available
Whether outcomes were clearly defined: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Mortality due to tumour lysis syndrome
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Blinding was not used
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Patte 2002 (Continued)
Incomplete outcome data (attrition bias)
Mortality due to tumour lysis syndrome
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk Comparability of the treatment groups at
baseline was uncertain because baseline
characteristics of comparison groups were
not available. Potential confounders were
not adjusted. Chemotherapy treatments
were different in different centres in differ-
ent locations, which may cause bias
Pui 1997
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with non-B-cell ALL
Exclusion criteria: participants with history of allergy, G6PD deficiency or pregnancy,
or who had not received methotrexate or 6-mercaptopurine as preinduction therapy
Number of participants (intervention/comparison): 119/129
Number of boys (intervention/comparison): not available
Age (intervention/comparison): (median) 5.6/5.7 years
Underlying haematological malignancies (intervention/comparison): all non-B-cell ALL
Baseline WBC (intervention/comparison): (median) 11.7/13.8 x 10 /L
Baseline uric acid (intervention/comparison): (median) 4.3/4.3 mg/dL
Baseline lactate dehydrogenase (intervention/comparison): (median) 1243/957 U/L
Baseline BUN (intervention/comparison): (median) 8.0/8.0 mg/dL
Baseline creatinine (intervention/comparison): (median) 0.5/0.5 mg/dL
Baseline calcium (intervention/comparison): (median) 9.4/9.4 mg/dL
Baseline phosphate (intervention/comparison): (median) 4.9/4.7 mg/dL
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol
Treatment regime in intervention group: Uricozyme 100 units/kg ivi over 30 min daily
for 5 d
Treatment regime in comparison group: allopurinol 300 mg/m²/d orally for 5-13 d
Cointerventions: hydration with NaHCO to maintain urine pH≥ 6.5; oral phosphate
binders (aluminium hydroxide or calcium carbonate) were given to participants as indi-
cated
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Pui 1997 (Continued)
Outcomes • Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 13 days
Number of dropouts (intervention/comparison): 0/0
Potential confounders were adjusted
The intervention and the control groups appeared comparable at baseline
Whether outcomes were clearly defined: yes
The report of adverse events included additional 15 participants who had received an
incomplete course of Uricozyme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Serial uric acid level
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Blinding was not used
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Serial uric acid level
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Adverse events
Low risk The outcome data were complete for the
groups of participants analysed
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Pui 1997 (Continued)
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk Potential confounders were not adjusted.
Use of historical controlmay bias the results
in favour of the newer treatment because of
improvement in supportive care
Rényi 2007
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants aged 6 months-18 years with a recent diagnosis
of B-cell lineage ALL with an initial WBC ≥ 25,000/uL, or high-grade non-Hodgkin’s
lymphoma, or any type of ALL or NHL with a plasma uric acid ≥ 480 mmol/L and
LDH > 500 IU/L, or either a creatinine or an LDH concentration > twice the upper
limit of normal
Exclusion criteria: history of clinically significant atopic allergy, bronchial asthma, G6PD
deficiency or any type of haemolytic anaemia, previous treatmentwith rasburicase or non-
recombinant urate oxidase, hypersensitivity reaction against ingredients of the present
preparation used in the study, participation in another drug experiment, pregnancy or
lactation
Number of participants (intervention/comparison): 12/14
Number of boys (intervention/comparison): 6/6
Age (intervention/comparison): (median) 4.5/6
Underlying haematological malignancies (intervention/comparison): leukaemia 8/13;
lymphoma 4/1
Baseline creatinine (intervention/comparison): median 65 (range = 32-85)/80 (range =
17-353) umol/L
Baseline uric acid (intervention/comparison): median 323 (range = 139-1059)/207
(range = 51-785) umol/L
Baseline phosphate (intervention/comparison): median 1.32 (range = 0.97-1.64)/1.62
(range = 0.98-1.33) mmol/L
Baseline LDH(intervention/comparison): 1909 (range = 497-9760)/3193 (236-20,560)
U/L
Baseline WBC (intervention/comparison): 51.8 (range = 2-651)/56 (range = 0.4-551) x
109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 min daily for
5 d from day 1 of antineoplastic treatment
Treatment regime in comparison group: allopurinol 300mg/m²/d or 10mg/kg/d divided
every 8 h for 5-7 d
Cointerventions: hydration 3 L/m²/d, iv sodium bicarbonate 20-40 mmol/L tomaintain
urine pH 6.5-7
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Rényi 2007 (Continued)
Outcomes • All-cause mortality
• Mortality due to TLS
• Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 12 d
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group had
more participants with lymphoma, higher uric acid level, lower LDH level, lower serum
creatinine, and phosphorus
Whether outcomes were clearly defined: yes
The report of adverse events included additional 24 participants who had received ras-
buricase in other centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All-cause mortality
Low risk Assessment of death is unlikely to be mis-
taken or biased, even though outcome as-
sessors knew which treatment participants
were assigned
Blinding of outcome assessment (detection
bias)
Mortality due to tumour lysis syndrome
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Serial uric acid level
High risk Blinding was not used
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Rényi 2007 (Continued)
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All-cause mortality
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Mortality due to tumour lysis syndrome
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Serial uric acid level
High risk Serum uric acid data at 24-288 hours post-
treatmentweremissing in 6-12participants
(43%-86%)
Incomplete outcome data (attrition bias)
Adverse events
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because the treatment group had
more participants with lymphoma, higher
uric acid level, lower LDH level, lower
serum creatinine, and phosphorus. Poten-
tial confounders were not adjusted. Use of
historical control may bias the results in
favour of the newer treatment because of
improvement in supportive care
Sánchez Tatay 2010
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with haematological malignancies with TLS or
at risk of TLS, with at least 1 of the following criteria: WBC > 50,000/uL or lactate
dehydrogenase > 500 U/L; uric acid level ≥ 8 mg/dL or creatinine > 2 mg/dL; history
of TLS in previous cycles of chemotherapy
Exclusion criteria: participants with history of hypersensitivity to rasburicase or allopuri-
nol, asthma, atopy, G6PD deficiency, or other metabolic causes of haemolytic anaemia
Number of participants (intervention/comparison): 16/16
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Sánchez Tatay 2010 (Continued)
Number of boys (intervention/comparison): not available
Age (intervention/comparison): not available
Underlying haematological malignancies (intervention/comparison): not available
Baseline uric acid (intervention/comparison): (median) 10.6 (SD 3.2)/11.3 (SD 5.8)
mg/dL
Baseline creatinine (intervention/comparison): (median) 0.93 (SD 0.81)/1.01 (SD 0.
51) mg/dL
Baseline phosphate (intervention/comparison): (median) 6.28 (SD 2.29)/6.72 (SD 5.
02) mg/dL
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi daily (duration of
treatment was not mentioned)
Treatment regime in comparison group: allopurinol 10 mg/kg/d divided every 8 h (du-
ration of treatment was not mentioned)
Cointerventions: not mentioned
Outcomes • All-cause mortality
• Mortality due to TLS
• Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 4 d
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
Comparability of the treatment groups at baseline was uncertain because some important
baseline characteristics of comparison groups were not available
Whether outcomes were clearly defined: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All-cause mortality
Low risk Assessment of death is unlikely to be mis-
taken or biased, even though outcome as-
sessors knew which treatment participants
were assigned
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Sánchez Tatay 2010 (Continued)
Blinding of outcome assessment (detection
bias)
Mortality due to tumour lysis syndrome
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Serial uric acid level
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All-cause mortality
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Mortality due to tumour lysis syndrome
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Serial uric acid level
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Adverse events
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk Comparability of the treatment groups at
baseline was uncertain because some im-
portant baseline characteristics of compar-
ison groups were not available. Potential
confounders were not adjusted. Use of his-
torical controlmay bias the results in favour
of the newer treatment because of improve-
ment in supportive care
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Wössmann 2003
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants ≤ 18 years with B-ALL or stage III and IV
B-NHL and LDH ≥ 500 U/L treated in the trials NHL-BFM 90 and 95, during the
periodNovember 1997-December 2001 (intervention group) orApril 1990-March 1996
(comparison group)
Exclusion criteria: nil
Number of participants (intervention/comparison): 130/218
Number of boys (intervention/comparison): N/A
Age (intervention/comparison): N/A
Underlying haematological malignancies: B-ALL 53/78; B-NHL 77/140
Baseline elevated LDH > 1000 U/L (intervention/comparison): 49.6%/47.2%
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol and alkalinization
Treatment regime in intervention group: Uricozyme 3 x 50 U/kg/d for 3-4 d
Treatment regime in comparison group: allopurinol 10 mg/kg/d + alkalinization to
maintain urine pH 7
Cointerventions: hydration 3 to 4.5 L/m²/d
Outcomes • Incidence of clinical TLS
• All-cause mortality
• Incidence of renal failure requiring renal replacement therapy
Notes Duration of follow up not reported
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group had fewer
participants who were critically ill or had complications after initial surgery
Whether outcomes were clearly defined: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
Incidence of clinical tumour lysis syndrome
High risk Blinding was not used
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Wössmann 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All-cause mortality
Low risk Assessment of death is unlikely to be mis-
taken or biased, even though outcome as-
sessors knew which treatment participants
were assigned
Blinding of outcome assessment (detection
bias)
Renal failure requiring renal replacement
therapy
High risk Blinding was not used
Incomplete outcome data (attrition bias)
Incidence of clinical tumour lysis syndrome
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
All-cause mortality
Low risk The outcome data were complete for the
groups of participants analysed
Incomplete outcome data (attrition bias)
Renal failure requiring renal replacement
therapy
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because the treatment group had
fewer participants who were critically ill or
had complications after initial surgery. Po-
tential confounders were not adjusted. Use
of historical control may bias the results in
favour of the newer treatment because of
improvement in supportive care
ALL: acute lymphoblastic leukaemia
ALT: alanine aminotransferase
B-NHL: B cell non-Hodgkin lymphoma
BUN: blood urea nitrogen
CCT: controlled clinical trial
ECOG: Eastern Cooperative Oncology Group
G6PD: glucose-6-phosphate dehydrogenase deficiency
HBsAg: hepatitis B virus surface antigen
HCV: hepatitis C virus
iv: intravenous
ivi: intravenous infusion
LDH: lactate dehydrogenase
N/A: information not available
NHL: non-Hodgkin lymphoma
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RCT: randomised controlled trial
SD: standard deviation
TLS: tumour lysis syndrome
WBC: white blood cell (count)
UKCCSG: United Kingdom Children’s Cancer Study Group
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cortes 2010 This was an RCT recruiting adult participants only and no paediatric participants
Ishizawa 2009 This was an RCT recruiting adult participants only and no paediatric participants
Vadhan-Raj 2012 This was an RCT recruiting adult participants only and no paediatric participants
RCT :randomisedcontrolledtrial.
Characteristics of ongoing studies [ordered by study ID]
NCT00199043
Trial name or title Randomised phase III trial of effectivity and safety of rasburicase compared with allopurinol for treatment of
hyperuricemia in patients with acute lymphoblastic leukemia or high-grade NHL with high risk of tumour
lysis syndrome (> 15 yrs)
Methods RCT
Participants Participants aged above 15 years, participating in the GMALL B-ALL/NHL-Study 2002; the GMALL-Study
07/2003; or the GMALL-Study Elderly 1/2003 that fulfil the following criteria: bulky disease (> 7.5 cm)
, high LDH (> 2 times the upper limit of normal), uric acid > 8 mg/dl (> 475 µmol/L) at diagnosis, and
leukocytes > 30000/µL
Interventions Arm 1: allopurinol
Arm 2: rasburicase
Outcomes Primary outcomes: renal function, uric acid, electrolytes, adverse events, mortality in pre-phase and the 2
following cycles of chemotherapy, time and dose compliance of chemotherapy
Secondary outcomes: response rate, incidence of TLS
Starting date May 2003
Contact information Dieter Hoelzer, University Hospital, Medical Dept. II, Frankfurt, Germany, 60590
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NCT00199043 (Continued)
Notes Study completed. Results not available yet. Not all participants are eligible for this review (for example, elderly
participants may be included in this study)
NCT01200485
Trial name or title A randomized phase 2 study to evaluate the efficacy of rasburicase in patients at risk for TLS during two
cycles of chemotherapy
Methods RCT
Participants Participants that are high risk for TLS or potential/intermediate risk for TLS as described below. (a) High
risk: hyperuricaemia of malignancy (uric acid levels > 7.5 mg/dL); or diagnosis of very aggressive lymphoma/
leukaemia based on Revised European-American Lymphoma (REAL) classification; acute myeloid leukaemia,
CML in blast crisis; high-grade myelodysplastic syndrome only if they have > 10% bone marrow blast
involvement and given aggressive treatment similar to acute myeloid leukaemia. (B) Potential risk: diagnosis
of aggressive lymphoma/leukaemia based on REAL classification, plus 1 or more of the following criteria:
LDH >/= 2 times the upper limit of normal; stage III-IV disease; stage I-II disease with at least 1 lymph node/
tumour > 5 cm in diameter. For participants with potential/intermediate risk for TLS, only those planned
to receive alternating regimens (or non-standard regimens) in 2 cycles (example; R-Hyper-CVAD alternating
with MTX/ARA-C) will be eligible
Interventions Arm A: Cycle 2 chemotherapy, rasburicase 0.15 mg/kg IV d 1, additional dose on days 2-5 at physician’s
discretion
Arm B: Cycle 2 chemotherapy, allopurinol 300 mg/d IV days 1-5 + rasburicase 0.15 mg/kg IV d 1 if uric acid
blood levels dictate single dose or more
Outcomes Primary outcome: incidence of laboratory TLS during cycle 2 (as defined by the Cairo-Bishop criteria)
Starting date May 2011
Contact information Saroj Vadhan-Raj, UT MD Anderson Cancer Center, Houston, Texas, United States, 77030
Telephone: +1 713 792 7966
Notes Ongoing study recruiting participants. Not all participants are eligible for this review (for example, elderly
participants may be included in this study)
CML: chronic myelogenous leukaemia
R-Hyper-CVAD: chemotherapy regimen consisting of rituximab, cyclophosphamide, vincristine, adriamycin, dexamethasone
LDH: lactate dehydrogenase
MTX/ARA-C: methotrexate and cytarabine
NHL: non-Hodgkin lymphoma
RCT: randomised controlled trial
TLS: tumour lysis syndrome
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D A T A A N D A N A L Y S E S
Comparison 1. Urate oxidase compared with allopurinol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of clinical tumour lysis
syndrome
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 CCT 1 348 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.44, 1.33]
2 Incidence of clinical tumour lysis
syndrome in B-ALL subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.18, 1.18]
3 All-cause mortality 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 CCT 3 406 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.42]
4 Mortality due to tumour lysis
syndrome
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 CCT 3 396 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.89]
5 Renal failure requiring renal
replacement therapy
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 CCT 5 992 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.08, 0.89]
6 Renal failure requiring renal
replacement therapy in B-ALL
subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.06, 1.05]
7 AUC of serum uric acid level at
4 days
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 RCT 1 52 Mean Difference (IV, Fixed, 95% CI) -201.0 [-258.05, -
143.95]
8 AUC of serum uric acid level at 4
days in leukaemia participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 RCT 1 39 Mean Difference (IV, Fixed, 95% CI) -220.0 [-286.67, -
153.33]
9 AUC of serum uric acid level at 4
days in lymphoma participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 RCT 1 13 Mean Difference (IV, Fixed, 95% CI) -132.0 [-185.47, -
78.53]
10 AUC of serum uric acid level
at 4 days in hyperuricemic
participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 RCT 1 19 Mean Difference (IV, Fixed, 95% CI) -278.0 [-373.69, -
182.31]
11 AUC of serum uric acid level
at 4 days in normouricemic
participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 RCT 1 33 Mean Difference (IV, Fixed, 95% CI) -240.0 [-340.95, -
139.05]
12 Serum uric acid level at 2 days 3 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 CCT 3 294 Mean Difference (IV, Random, 95% CI) -3.80 [-7.37, -0.24]
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13 Serum uric acid level at 3 days 2 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 CCT 2 47 Mean Difference (IV, Random, 95% CI) -3.13 [-6.12, -0.14]
14 Serum uric acid level at 4 days 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 CCT 2 45 Mean Difference (IV, Fixed, 95% CI) -4.6 [-6.39, -2.81]
15 Serum uric acid level at 7 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 CCT 1 16 Mean Difference (IV, Fixed, 95% CI) -1.74 [-3.01, -0.47]
16 Serum uric acid level at 1 day 3 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 CCT 3 298 Mean Difference (IV, Random, 95% CI) -3.00 [-7.61, 1.60]
17 Serum uric acid level at 5 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 CCT 1 14 Mean Difference (IV, Fixed, 95% CI) -1.02 [-2.24, 0.20]
18 Serum uric acid level at 12 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 CCT 1 20 Mean Difference (IV, Fixed, 95% CI) -0.80 [-2.51, 0.91]
19 Frequency of adverse events 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 CCT 3 345 Risk Ratio (M-H, Fixed, 95% CI) 9.10 [1.29, 64.00]
Comparison 2. High-dose urate oxidase compared with low-dose urate oxidase
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Normalisation of serum uric acid 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 RCT 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.28]
2 Percentage reduction in serum
uric acid level at 4 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 RCT 1 29 Mean Difference (IV, Fixed, 95% CI) 8.10 [-0.99, 17.19]
3 Frequency of adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 RCT 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.12, 2.48]
Analysis 1.1. Comparison 1 Urate oxidase compared with allopurinol, Outcome 1 Incidence of clinical
tumour lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 1 Incidence of clinical tumour lysis syndrome
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 16/130 35/218 100.0 % 0.77 [ 0.44, 1.33 ]
Subtotal (95% CI) 130 218 100.0 % 0.77 [ 0.44, 1.33 ]
Total events: 16 (Urate oxidase), 35 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours urate oxidase Favours allopurinol
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Analysis 1.2. Comparison 1 Urate oxidase compared with allopurinol, Outcome 2 Incidence of clinical
tumour lysis syndrome in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 2 Incidence of clinical tumour lysis syndrome in B-ALL subgroup
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 5/53 16/78 100.0 % 0.46 [ 0.18, 1.18 ]
Subtotal (95% CI) 53 78 100.0 % 0.46 [ 0.18, 1.18 ]
Total events: 5 (Urate oxidase), 16 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours urate oxidase Favours allopurinol
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Analysis 1.3. Comparison 1 Urate oxidase compared with allopurinol, Outcome 3 All-cause mortality.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 3 All-cause mortality
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
R nyi 2007 0/12 0/14 Not estimable
S nchez Tatay 2010 0/16 0/16 Not estimable
Wo¨ssmann 2003 0/130 4/218 100.0 % 0.19 [ 0.01, 3.42 ]
Subtotal (95% CI) 158 248 100.0 % 0.19 [ 0.01, 3.42 ]
Total events: 0 (Urate oxidase), 4 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 1.4. Comparison 1 Urate oxidase compared with allopurinol, Outcome 4 Mortality due to tumour
lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 4 Mortality due to tumour lysis syndrome
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Patte 2002 0/152 11/186 100.0 % 0.05 [ 0.00, 0.89 ]
R nyi 2007 0/12 0/14 Not estimable
S nchez Tatay 2010 0/16 0/16 Not estimable
Subtotal (95% CI) 180 216 100.0 % 0.05 [ 0.00, 0.89 ]
Total events: 0 (Urate oxidase), 11 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.042)
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Analysis 1.5. Comparison 1 Urate oxidase compared with allopurinol, Outcome 5 Renal failure requiring
renal replacement therapy.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 5 Renal failure requiring renal replacement therapy
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CCT
Patte 2002 4/152 38/186 35.6 % 0.13 [ 0.05, 0.35 ]
Pui 1997 0/119 0/129 Not estimable
R nyi 2007 0/12 1/14 11.6 % 0.38 [ 0.02, 8.65 ]
S nchez Tatay 2010 0/16 6/16 13.6 % 0.08 [ 0.00, 1.26 ]
Wo¨ssmann 2003 8/130 20/218 39.2 % 0.67 [ 0.30, 1.48 ]
Subtotal (95% CI) 429 563 100.0 % 0.26 [ 0.08, 0.89 ]
Total events: 12 (Urate oxidase), 65 (Allopurinol)
Heterogeneity: Tau2 = 0.83; Chi2 = 7.96, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.15 (P = 0.031)
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Analysis 1.6. Comparison 1 Urate oxidase compared with allopurinol, Outcome 6 Renal failure requiring
renal replacement therapy in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 6 Renal failure requiring renal replacement therapy in B-ALL subgroup
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 2/53 12/78 100.0 % 0.25 [ 0.06, 1.05 ]
Subtotal (95% CI) 53 78 100.0 % 0.25 [ 0.06, 1.05 ]
Total events: 2 (Urate oxidase), 12 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 1.7. Comparison 1 Urate oxidase compared with allopurinol, Outcome 7 AUC of serum uric acid
level at 4 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 7 AUC of serum uric acid level at 4 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 27 128 (70) 25 329 (129) 100.0 % -201.00 [ -258.05, -143.95 ]
Subtotal (95% CI) 27 25 100.0 % -201.00 [ -258.05, -143.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.91 (P < 0.00001)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours urate oxidase Favours allopurinol
52Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Urate oxidase compared with allopurinol, Outcome 8 AUC of serum uric acid
level at 4 days in leukaemia participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 8 AUC of serum uric acid level at 4 days in leukaemia participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 20 141 (75) 19 361 (129) 100.0 % -220.00 [ -286.67, -153.33 ]
Subtotal (95% CI) 20 19 100.0 % -220.00 [ -286.67, -153.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Urate oxidase compared with allopurinol, Outcome 9 AUC of serum uric acid
level at 4 days in lymphoma participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 9 AUC of serum uric acid level at 4 days in lymphoma participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 7 92 (41) 6 224 (55) 100.0 % -132.00 [ -185.47, -78.53 ]
Subtotal (95% CI) 7 6 100.0 % -132.00 [ -185.47, -78.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Urate oxidase compared with allopurinol, Outcome 10 AUC of serum uric
acid level at 4 days in hyperuricemic participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 10 AUC of serum uric acid level at 4 days in hyperuricemic participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 10 162 (87) 9 440 (121) 100.0 % -278.00 [ -373.69, -182.31 ]
Subtotal (95% CI) 10 9 100.0 % -278.00 [ -373.69, -182.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Urate oxidase compared with allopurinol, Outcome 11 AUC of serum uric
acid level at 4 days in normouricemic participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 11 AUC of serum uric acid level at 4 days in normouricemic participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 17 108 (51) 16 348 (200) 100.0 % -240.00 [ -340.95, -139.05 ]
Subtotal (95% CI) 17 16 100.0 % -240.00 [ -340.95, -139.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours urate oxidase Favours allopurinol
55Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 Urate oxidase compared with allopurinol, Outcome 12 Serum uric acid level
at 2 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 12 Serum uric acid level at 2 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
Pui 1997 119 1.1 (3.57) 129 2.8 (4.73) 41.3 % -1.70 [ -2.74, -0.66 ]
R nyi 2007 12 0.98 (1.38) 2 4.63 (3.91) 21.3 % -3.65 [ -9.12, 1.82 ]
S nchez Tatay 2010 16 0.5 (1.5) 16 6.7 (3.9) 37.5 % -6.20 [ -8.25, -4.15 ]
Subtotal (95% CI) 147 147 100.0 % -3.80 [ -7.37, -0.24 ]
Heterogeneity: Tau2 = 7.74; Chi2 = 14.89, df = 2 (P = 0.00058); I2 =87%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Urate oxidase compared with allopurinol, Outcome 13 Serum uric acid level
at 3 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 13 Serum uric acid level at 3 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
R nyi 2007 12 0.67 (0.64) 3 2.32 (1.03) 51.5 % -1.65 [ -2.87, -0.43 ]
S nchez Tatay 2010 16 0.4 (0.7) 16 5.1 (3.2) 48.5 % -4.70 [ -6.31, -3.09 ]
Subtotal (95% CI) 28 19 100.0 % -3.13 [ -6.12, -0.14 ]
Heterogeneity: Tau2 = 4.12; Chi2 = 8.79, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Urate oxidase compared with allopurinol, Outcome 14 Serum uric acid level
at 4 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 14 Serum uric acid level at 4 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 0.3 (0.3) 1 1.43 (0) Not estimable
S nchez Tatay 2010 16 0.2 (0.6) 16 4.8 (3.6) 100.0 % -4.60 [ -6.39, -2.81 ]
Subtotal (95% CI) 28 17 100.0 % -4.60 [ -6.39, -2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Urate oxidase compared with allopurinol, Outcome 15 Serum uric acid level
at 7 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 15 Serum uric acid level at 7 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 1.43 (1.06) 4 3.17 (1.14) 100.0 % -1.74 [ -3.01, -0.47 ]
Subtotal (95% CI) 12 4 100.0 % -1.74 [ -3.01, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours urate oxidase Favours allopurinol
Analysis 1.16. Comparison 1 Urate oxidase compared with allopurinol, Outcome 16 Serum uric acid level
at 1 day.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 16 Serum uric acid level at 1 day
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
Pui 1997 119 1 (3.81) 129 3.4 (5.64) 36.1 % -2.40 [ -3.59, -1.21 ]
R nyi 2007 12 6.17 (3.38) 6 4.12 (4.54) 28.6 % 2.05 [ -2.06, 6.16 ]
S nchez Tatay 2010 16 0.5 (1.7) 16 8.2 (2.8) 35.4 % -7.70 [ -9.31, -6.09 ]
Subtotal (95% CI) 147 151 100.0 % -3.00 [ -7.61, 1.60 ]
Heterogeneity: Tau2 = 14.92; Chi2 = 35.69, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Urate oxidase compared with allopurinol, Outcome 17 Serum uric acid level
at 5 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 17 Serum uric acid level at 5 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 0.44 (0.48) 2 1.46 (0.86) 100.0 % -1.02 [ -2.24, 0.20 ]
Subtotal (95% CI) 12 2 100.0 % -1.02 [ -2.24, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Urate oxidase compared with allopurinol, Outcome 18 Serum uric acid level
at 12 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 18 Serum uric acid level at 12 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 2.34 (1.49) 8 3.14 (2.14) 100.0 % -0.80 [ -2.51, 0.91 ]
Subtotal (95% CI) 12 8 100.0 % -0.80 [ -2.51, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Urate oxidase compared with allopurinol, Outcome 19 Frequency of adverse
events.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 19 Frequency of adverse events
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Pui 1997 7/134 0/129 41.7 % 14.44 [ 0.83, 250.35 ]
R nyi 2007 6/36 0/14 58.3 % 5.27 [ 0.32, 87.82 ]
S nchez Tatay 2010 0/16 0/16 Not estimable
Subtotal (95% CI) 186 159 100.0 % 9.10 [ 1.29, 64.00 ]
Total events: 13 (Urate oxidase), 0 (Allopurinol)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 1
Normalisation of serum uric acid.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 1 Normalisation of serum uric acid
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 14/14 14/15 100.0 % 1.07 [ 0.89, 1.28 ]
Subtotal (95% CI) 14 15 100.0 % 1.07 [ 0.89, 1.28 ]
Total events: 14 (High dose), 14 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 2
Percentage reduction in serum uric acid level at 4 hours.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 2 Percentage reduction in serum uric acid level at 4 hours
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Kikuchi 2009 14 92.9 (7.9) 15 84.8 (16) 100.0 % 8.10 [ -0.99, 17.19 ]
Subtotal (95% CI) 14 15 100.0 % 8.10 [ -0.99, 17.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 3
Frequency of adverse events.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 3 Frequency of adverse events
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 2/14 4/15 100.0 % 0.54 [ 0.12, 2.48 ]
Subtotal (95% CI) 14 15 100.0 % 0.54 [ 0.12, 2.48 ]
Total events: 2 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)
The following text words were used:
urate oxidase OR uricase OR uricas* rasburicase OR rasburicas* OR elitek OR fasturtec OR fasturt* OR uox
The search was performed in title, abstract or keywords
[*=zero or more characters]
Appendix 2. Search strategy for PubMed
1. For Urate oxidase the following MeSH headings and text words were used:
urate oxidase OR uricase OR uricas* OR oxidase, urate OR EC 1.7.3.3. OR rasburicase OR rasburicas* OR elitek OR fasturtec OR
fasturt* OR uox
2. For Children the following MeSH headings and text words were used:
infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR
schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen*
OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR
puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary
school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery
OR infant, newborn
3. For Cochrane RCTs/CCTs the following MeSH headings and text words were used in the original version of the review:
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw])
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo*
[tw] OR random* [tw] OR research design [mh:NoExp]OR comparative study [mh]OR evaluation studies [mh]OR follow-up studies
[mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans
[mh]))
For the update in 2013 the following search strategy for identifying RCTs and CCTs was used:
((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh])
OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) AND (humans[mh])
Final search: 1 AND 2 AND 3
[CCT = controlled clinical trial; RCT = randomized controlled trial; mh = Medical Subject Heading (MeSH) term; pt =publication
type; tw: text word]
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Appendix 3. Search strategy for Embase (OVID)
1. For Urate oxidase the following Emtree terms and text words were used:
1. urate oxidase.mp. or Urate Oxidase/
2. (rasburicase or uox).mp.
3. (uricase or elitek).mp.
4. (9002-12-4 or 352311-12-7).rn. or EC 1733.mp.
5. (uricas$ or rasburicas$ or fasturtec or fasturt$).mp.
6. or/1-5
2. For Children the following Emtree terms and text words were used:
1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
4. or/1-3
5. (infant$ or (newborn$ or new born$) or (baby or baby$ or babies) or neonate$).mp.
6. (child$ or (school child$ or schoolchild$) or (school age$ or schoolage$) or (pre school$ or preschool$)).mp.
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
8. (minors$ or (under ag$ or underage$) or juvenil$ or youth$).mp.
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
10. (pediatric$ or paediatric$ or peadiatric$).mp.
11. (school or schools or (high school$ or highschool$) or primary school$ or nursery school$ or elementary school or secondary
school$ or kindergar$).mp.
12. or/5-11
13. 4 or 12
3. For RCTs/CCTs the following Emtree terms and text words were used in the original version of the review:
1. Clinical Trial/
2. Controlled Study/
3. Randomized Controlled Trial/
4. Double Blind Procedure/
5. Single Blind Procedure/
6. Comparative Study/
7. RANDOMIZATION/
8. Prospective Study/
9. PLACEBO/
10. Phase 2 Clinical Trial/
11. phase 3 clinical study.mp.
12. phase 4 clinical study.mp.
13. Phase 3 Clinical Trial/
14. Phase 4 Clinical Trial/
15. or/1-14
16. allocat$.mp.
17. blind$.mp.
18. control$.mp.
19. placebo$.mp.
20. prospectiv$.mp.
21. random$.mp.
22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.
23. (versus or vs).mp.
24. (randomized controlled trial$ or randomised controlled trial$).mp.
25. controlled clinical trial$.mp.
26. clinical trial$.mp.
27. or/16-27
28. Human/
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29. Nonhuman/
30. ANIMAL/
31. Animal Experiment/
32. or/29-31
33. 32 not 28
34. (15 or 27) not 33
For the update in 2013 the following search strategy for identifying RCTs and CCTs was used:
1. Randomized Controlled Trial/
2. Controlled Clinical Trial/
3. randomized.ti,ab.
4. placebo.ti,ab.
5. randomly.ti,ab.
6. trial.ti,ab.
7. groups.ti,ab.
8. drug therapy.sh.
9. or/1-8
10. Human/
11. 9 and 10
Final search: 1 and 2 and 3 (Urate oxidase AND Children AND RCT)
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name;
sh = subject heading; ti,ab = title, abstract; / = Emtree term; $ = zero or more characters; rn = registry number; RCT = randomized
controlled trial; CCT = controlled clinical trial]
Appendix 4. Search strategy for CINAHL
1. For Urate oxidase the following text words were used:
urate oxidase OR rasburicase OR uox OR uricase OR elitek OR fasfurtec
2. For Children the following text words were used:
neonate OR infant OR newborn OR baby OR child OR preschool OR school OR adolescent OR juvenile OR boy OR girl OR
puberty OR pediatric OR kindergarten OR nursery OR kid OR minors
3. For RCTs/CCTs the following text words were used:
trial OR control OR placebo OR random OR prospective study OR comparative study
In the final search the three searches were combined: 1 AND 2 AND 3
Appendix 5. Search strategy for internet sources
(urate oxidase OR rasburicase OR uricase OR elitek OR fasfurtec) AND child AND tumour lysis
Appendix 6. Search strategy for conference proceedings
(urate oxidase OR rasburicase OR uricase OR elitek OR fasfurtec) AND child AND tumour lysis AND trial
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WH A T ’ S N E W
Date Event Description
14 March 2016 New search has been performed The search for eligible studies was updated to March
2016.
14 March 2016 New citation required but conclusions have not changed Unfortunately, no new studies could be included in the
review. As a result the conclusions have not changed.
In this version of the review, we have used the most re-
cent ’Risk of bias’ criteria as recommended by Cochrane
Childhood Cancer and we have included ’Summary of
findings’ tables and performed a GRADE assessment
H I S T O R Y
Date Event Description
1 August 2013 New citation required and conclusions have changed Two new studies were found and included in the up-
date. Conclusions regarding efficacy outcomes did not
change, whereas for adverse effects they did
26 February 2013 New search has been performed The search for eligible studies was updated to February
2013
17 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Cheuk DKL: protocol development, searching for trials, ’Risk of bias’ assessment and GRADE assessment of trials, data extraction,
data input, data analyses, development of final review, preparation of ’Summary of findings’ table, corresponding author.
Chiang AKS: protocol development, ’Risk of bias’ assessment of trials, data extraction, data input, data analyses, development of final
review.
Chan GCF: protocol development, development of final review.
Ha SY: protocol development, development of final review.
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S O U R C E S O F S U P P O R T
Internal sources
• The Library of The University of Hong Kong, Hong Kong.
The Library of The University of Hong Kong provided support in retrieving full-texts of studies.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Weused themean difference for continuous outcomes instead of the weightedmean difference.We updated the ’Risk of bias’ assessment
according to the latest version of theCochrane Handbook for Systematic Reviews of Interventions (version 5.1.0).We still reported outcomes
with less than 70% of participants’ data, but we considered them to be prone to bias. We did not calculate risk ratio if there was only
one study available for a particular outcome and there was no event in one of the groups; we used the Fisher’s exact test (performed
using SPSS 19) to determine the P value in such situations. In the update 2013, we changed the unit of uric acid measurements to
mg/dL, instead of micromol/L in the original review, as mg/dL appeared to be more widely used. In the update 2016, we included
GRADE assessment and ’Summary of findings’ table and updated risk of bias assessment.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Allopurinol [therapeutic use]; Antimetabolites [therapeutic use]; Area Under Curve; Controlled Clinical Trials as Topic; Neoplasms
[∗drug therapy]; Randomized Controlled Trials as Topic; Renal Insufficiency [prevention& control]; Tumor Lysis Syndrome [mortality;
∗prevention & control]; Urate Oxidase [∗therapeutic use]; Uric Acid [blood]
MeSH check words
Adolescent; Child; Humans
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